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Abstract 
Genetically engineered T cells are a promising therapeutic tool for the treatment of cancer 
or infectious diseases. The generation of potent chimeric antigen receptor (CAR) T cells 
for clinical use, however, is associated with a plurality of challenges covering medical, 
economical as well as scientific aspects. Therefore, the present study focusses on specific 
medical and technical difficulties limiting the dissemination of adoptive cellular therapies 
(ACT). Furthermore, strategies aiming to improve the potential of CAR modified T cells, 
especially in a solid tumor setting, were investigated. 
To this effect, our work initially focused on the generation of a novel CD20-directed CAR 
which we evaluated in newly established in vitro and in vivo assays. After confirming the 
potency of the anti-CD20 CAR T cells, we focused on the manufacturing and consequently 
demonstrated that a current good manufacturing practice (cGMP)-compliant, automated 
T cell Transduction (TCT) Process is both reliable and applicable to manufacture CAR 
T cells in a clinically relevant scale and quality. Despite varying starting material, different 
operators or the use of other devices, the developed manufacturing process yielded a 
robust formulated product with regard to cellular composition, T cell phenotype or anti-
tumor potency. Overall, the high reproducibility of the TCT Process proved the suitability 
to manufacture CD20-directed CAR T cells which are intended to be used in two clinical 
trials. 
In addition, this work focused on strategies to enhance the CAR-based immune response 
in a melanoma model by co-expressing a CAR and a chimeric co-stimulatory receptor 
(CCR) in the same T cell. This two-receptor approach includes a second generation CAR 
specific for chondroitin sulfate proteoglycan 4 (CSPG4) and a CCR that recognizes CD20. 
Here we show that, dependent on intracellular CCR design, only a simultaneous activation 
of both co-expressed chimeric receptors CAR as well as CCR resulted in a significantly 
enhanced immune response. Altogether, this data supports the idea of using an anti-CD20 
CCR as a tool to increase the potential of CAR T cells.  
  
  
 
Zusammenfassung 
Genetisch modifizierte T-Zellen repräsentieren einen vielversprechenden klinischen 
Ansatz zur Behandlung von Krebs oder Infektionskrankheiten. Die Herstellung von 
chimären  Antigen-Rezeptor (CAR) T-Zellen für eine therapeutische Verwendung ist 
jedoch mit einer Vielzahl an medizinischen, wirtschaftlichen als auch wissenschaftlichen 
Herausforderungen assoziiert, die in der vorliegenden Arbeit gezielt adressiert wurden, 
um eine Ausweitung adoptiver zellulärer Therapien zu ermöglichen. Zudem wurden 
Strategien zur Steigerung des Potentials von CAR T-Zellen erforscht. 
Zunächst wurde ein neuer CD20-spezifischer CAR hergestellt und dessen Funktionalität 
mittels neu etablierter Verfahren evaluiert und sowohl in vitro als auch in vivo bestätigt. 
Anschließend fokussierten wir uns auf die Herstellung von genmodifizierten T-Zellen und 
zeigten, dass der hier etablierte und automatisierte T cell Transduction (TCT) Prozess 
dazu geeignet ist, um CAR T-Zellen good manufacturing practice (GMP)-gerecht und 
zuverlässig in einem klinisch relevanten Maßstab und entsprechend hoher Qualität zu 
generieren. Trotz variierendem Ausgangsmaterial, das von unterschiedlichen 
Experimentatoren an verschiedenen Geräten verwendet wurde, resultierte der TCT 
Prozess in einem stabil formulierten und einheitlichen Produkt bezüglich 
Zellzusammensetzung, T-Zell Phänotyp und Zytotoxizität. Aufgrund dieser 
Reproduzierbarkeit und Zuverlässigkeit qualifizierte sich der TCT Prozess zur Herstellung 
von CD20-gerichteten CAR T-Zellen, die in zwei klinischen Studien verwendet werden. 
Darüber hinaus wurde das Potential von chimären co-stimulatorischen Rezeptoren (CCR) 
zur Steigerung einer CAR-assoziierten Immunantwort in einem Melanom-Modell 
untersucht. Hierfür wurden T-Zellen generiert, die einen chondroitin sulfate proteoglycan 
4 (CSPG4)-spezifischen CAR und einen CD20-gerichteten CCR co-exprimieren. Wir 
zeigten, dass abhängig vom intrazellulärem CCR Aufbau nur eine simultane Aktivierung 
von CAR und CCR in einer signifikant gesteigerten Immunantwort resultieren. Insgesamt 
belegen die Daten die Möglichkeit zur Steigerung der Potentials von CARs durch die 
Verwendung entsprechender CCRs. 
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1  Introduction 
Cancer designates a malignant neoplasm of endogenous cells or tissue with the potential 
to invade adjacent tissues or to induce a metastatic growth in distant organs. As one of 
the main causes of death in developed countries, cancer still represents a fundamental 
medical challenge [1]. According to the Robert Koch-Institute, approximately 480.000 
cases are diagnosed every year in Germany with an increasing trend [2]. Thus, the 
development of novel and innovative therapies are of utmost importance. 
1.1  Conventional cancer treatment and novel strategies 
Traditional strategies for the treatment of cancer including surgery, radiation- or 
chemotherapy correspond to a “one size fits all approach” [3] which does not sufficiently 
consider the complexity of some cancer diseases. Hence, the chances of a cure using 
surgical treatments, the most effective option so far, requires an early tumor detection and 
decreases with disease progression. An adequate alternative was for a long time only the 
use of radiation- or chemotherapeutic therapies, however, although sometimes efficacious, 
the systemic approach is generally associated with severe toxicities for the patients [4]. 
Scientific progress and new findings in molecular oncology, though, led to the 
development of targeted therapies which considerably improved the treatment success 
for a multitude of cancer [3, 5, 6]. In this context, initial success was achieved with chimeric 
monoclonal antibodies like rituximab that induces anti-tumor reactions due to a broad 
versatility of mechanisms such as complement-dependent cytotoxicity, antibody-
dependent cytotoxicity or direct apoptosis triggering [7, 8]. Equally important are 
proteasome inhibitors like Bortezomib, a boron-containing pyridine-carboxamide, used for 
the treatment of patients with multiple myeloma which impedes the degradation of 
intracellular ubiquitinated proteins [9, 10]. The next major step towards individualized 
therapies allowed, amongst others, in-depth genomic investigation of tumors using next 
generation sequencing approaches and advanced bioinformatic tools. In this way, BRAF, 
a main protein of the RAS/RAF signaling pathway, or rather its mutation V600E, which is 
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present in approximately 60% of melanoma patients [11, 12], was detected and clinically 
approved as promising therapy approach for melanoma using the protein kinase inhibitor 
vemurafenib [13, 14]. 
In 2013, Science selected immunotherapy as “Breakthrough of the Year” [15]. They drew 
this decision based on the promising results of different therapeutic approaches exploiting 
the potency of the immunotherapy and acknowledged innovative and personalized 
medicine. Thus, immune checkpoint inhibitors like ipilimumab (anti-CTLA4) or nivolumab 
(anti-PD-1) prove the significance of modulating immunosuppression mechanisms in a 
clinical context [16-18] but also patient-derived and ex vivo expanded tumor-infiltrating 
lymphocytes (TILs) demonstrated their efficacy for the treatment of metastatic melanoma 
[19, 20]. Overall, “harnessing the immune system to battle tumors” [15] opens up a vast 
potential and particularly engineered T cells come to the forefront of adoptive cellular 
therapies (ACT). Basically, CAR T cell therapy is taking advantage of deep knowledge on 
targets and efficacy of T cell effector mechanisms. 
Almost three decades ago, Gross et al. [21] reported for the first time on genetically 
modified T cells expressing an artificial receptor used to specifically bind an antigen which 
resulted in a non-major histocompatibility complex (MHC)-restricted T cell response. 
These findings and following improvements paved the way from “basic immunology to 
paradigm-shifting clinical immunotherapy” [22]. In principle, the structure of this first 
chimeric receptor in contrast to the well-known first generation chimeric antigen receptors 
(CAR) did not greatly change. Hence, both generally comprise a specific binding domain 
(mostly a single-chain variable fragment (scFv) derived from an antibody), an extracellular 
spacer, a transmembrane domain and an intracellular domain containing an 
immunoreceptor tyrosine-based activation motif (ITAM) like CD3 [23] (Fig.  1).  
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However, T cells endowed with such a first generation CAR, even though functional in 
vitro, hardly proliferated or persisted in vivo and thus showed only modest clinical 
response [24, 25]. These findings demonstrated the need for further modifications to 
improve the potential of CAR T cells. Consequently, analogue to conventional T cell 
activation requiring not only `signal 1´ but also `signal 2´, a co-stimulatory domain such as 
CD28 or 4-1BB was added to the CD3 intracellular signaling domain. Those second 
generation CAR T cells outperformed the first generation and demonstrated remarkable 
clinical responses [26-31]. The incorporation of additional co-stimulatory domains in third 
generation CAR T cells were reported to further ameliorate CAR T cell potential [32-34], 
however, their clinical use might be also associated with risks, due to a very low activation 
threshold [35, 36]. Several clinical trials are currently assessing both safety and efficacy 
of third generation CAR T cells (e.g. ClinicalTrials.gov Identifier NCT02186860, 
NCT02132624 or NCT01853631). Fig.  2 summarizes essential characteristics of the 
different CAR generations. 
 
Fig.  1 First generation CAR T cell.  
CARs combine an extracellular binding 
moiety (mostly a scFv) with an 
intracellular T cell-derived signaling 
domain. T cells expressing such an 
artificial receptor are able to specifically 
bind an antigen and transmit an 
activation signal which mediates a 
MHC-independent target cell lysis. 
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Fig.  2 Different CAR generations. CARs have a modular design comprising an extracellular binding 
portion (scFv), a spacer as well as a transmembrane (TM) domain linked to intracellular signaling domain(s). 
While first generation CAR T cells only contain a CD3 signaling domain, second and third generation CARs 
additionally incorporate one or two co-stimulatory domains.  
The clinically approved second generation anti-CD19 CAR comprises the intracellular 
motif derived from CD28, however, latest findings showed that especially this co-
stimulatory domain, although functional in vivo, is associated with a poor persistency of 
CAR engineered T cells due to an early exhaustion [37]. In contrast to this, 4-1BB 
signaling in CAR T cells prevents this exhaustion effect resulting in both persistency and 
functionality [38]. In addition, for the generation of functional CARs, it has been shown 
that the design of extracellular motifs are of utmost importance as well. Thus, spatial 
biological correlations between effector cell and target have to be considered in the CAR 
design and by varying the spacer length, empirically adjusted [39]. Furthermore, activation 
induced cell death (AICD), caused by FcR binding to the spacer, has to be avoided [39, 
40]. Therefore, an appropriate extracellular stalk or modified spacer domains should be 
considered in the CAR design. 
The binding moiety, mostly an antibody-derived scFv, redirects the genetically engineered 
T cells to a defined target. However, an optimal binding depends on several factors 
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including antigen expression pattern, antigen expression level, actual affinity of an scFv 
for an antigen as well as the CAR expression on the T cells. Hence, especially in a solid 
tumor setting, high affinity CAR T cells have a great inherent potential to cause severe 
side effects by binding and destroying cells that express an antigen at a low level [41]. 
Indeed, low affinity scFvs allow a greater flexibility with regard to antigen choice, on the 
other hand might only induce a reduced T cell response [42]. 
One common risk which originates from all extracellular CAR domains is their potential 
immunogenicity. Accordingly, nearly all CAR constructs incorporate a human-derived 
stalk. But many scFvs, including FCM63 [43] in the anti-CD19 CAR and Leu-16 used in 
the anti-CD20 CAR [44], were derived from murine monoclonal antibodies and therefore 
might cause severe human-anti-mouse antibody (HAMA) responses; allergic-like 
reactions against the mouse peptides that aggravate with increasing treatment duration 
and repeating injections [45, 46]. Consequently, CAR T cells with scFv derived from 
chimeric or non-human antibodies might not only induce an anaphylactic reaction but also 
negatively affect the therapeutic outcome.  
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1.2  CAR T cells therapies: Status quo and challenges  
The success of CAR T cell therapies strongly depends on the availability of a suitable 
target antigen. Ideally, such an antigen is exclusively and homogenously expressed on 
tumor cells or at least shows a restricted expression on a defined cell population which 
can be considered as tolerable side effect during the treatment. Amongst others, -folate 
receptor for the treatment of ovarian cancer [47], mesothelin for the treatment of lung 
cancer (ClinicalTrials.gov Identifier NCT02414269), disialoganglioside GD2 for the 
treatment of neuroblastoma [48], epidermal growth factor receptor vIII for the treatment of 
malignant gliomas (ClinicalTrials.gov Identifier NCT01454596), epidermal growth factor 
receptor II for the treatment of colon cancer [41], prostate specific membrane antigen for 
the treatment of prostate cancer (ClinicalTrials.gov Identifier NCT00664196), carcio 
embryonic antigen for the treatment of adenocarcinoma (ClinicalTrials.gov Identifier 
01723306) and metastatic breast cancer (ClinicalTrials.gov Identifier 00673829) or CD30 
for the treatment of Hodgkin´s lymphoma (ClinicalTrials.gov Identifier NCT01316146) are 
already used as targets for CAR T cells as reviewed by Zhang et al. [49]. However, the 
current “poster child” is CD19 [50] which expression is limited to B cells and some B cell 
diseases [51]. Complete remission rates over 88% in patients suffering from relapsed or 
refractory acute lymphocytic leukemia (ALL) [52-54] and other success for chronic 
lymphocytic leukemia (CLL) [30, 31] and non-Hodgkin lymphoma (NHL) [28] have already 
been reported for CD19-directed CAR T cell therapies. But despite these remarkable 
achievements, there are also published setbacks for using CD19 as target. Thus, 60% of 
patient relapses during the treatment are caused by a loss of CD19 expression [55] as a 
result of genomic alterations and post-transcriptional modifications [56]. Such a loss is 
generally associated with a bad prognosis for the patients [57].  
In contrast to CD19, CD20 is a non-internalizing epitope [58, 59], widely expressed on 
B cells and B cell malignancies including diffuse large B-cell lymphoma (DLBCL), hairy 
cell leukemia (HCL) and to a lesser extend in CLL as well as in ALL. In addition, CD20 
was reported to be expressed on a minor subset of cancer-initiating melanoma cells [60, 
61]. Consequently, rituximab, a clinically approved CD20-directed chimeric monoclonal 
antibody for the treatment of lymphoma [62, 63], was used in case studies with metastatic 
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melanoma patients [64, 65] confirming “a potential therapeutic value” [64]. Finally, Till et 
al. [44] combined the potency of CD20-directed therapies with the inherent biological 
potential of T cells and generated an anti-CD20 CAR. He assessed in a proof-of-concept 
clinical trial (ClinicalTrials.gov Identifier NCT00012207) safety and feasibility for the 
treatment of patients suffering from refractory indolent NHL or mantle cell lymphoma 
(MCL) and concluded that “adoptive immunotherapy with anti-CD20 cTCR bearing T cells 
is safe, feasible, and well-tolerated”.  
The clinical potential of engineered T cells and particularly their dissemination to large 
patient numbers is limited regarding the complexity of the manufacturing process. In this 
context, not only technical demands but also statutory regulations are defining very high 
barriers [66]. Thus, the production of CAR T cells comprises a multitude of laborious, 
individual work steps including T cell isolation (optional), activation, modification, 
expansion and formulation. To prevent “contamination, cross contamination and, in 
general, any adverse effect to the quality of the product” (2003/94/EC of 8 October 2003), 
this work places extremely strict requirements on operators, facility and infrastructure [66]. 
In order to meet both Advanced Therapy Medicinal Products (ATMPs) specifications as 
well as the rising demand of engineered cells, automatization of at least sub-processes is 
necessary.  
While initial semi-automated protocols focused on cell expansion using e.g. G-Rex flasks 
(Wilson Wolf) or PermaLife bags (OriGen Biomedical) [67-69] and thus still depend on 
multiple open handling steps, Miltenyi Biotec developed a fully-closed, cGMP-compliant, 
automated T Cell Transduction (TCT) Process on the CliniMACS Prodigy. In collaboration 
projects with both Mock et al. [70] and Priesner et al. [71] the early feasibility to use this 
device to manufacture CAR engineered T cells was demonstrated. Due to the use of a 
single-use disposable tubing set which comprises a pump tubing, a separation column 
and a cultivation chamber (Fig.  3A) the risk of contaminations and particularly cross 
contaminations is strongly reduced. Defined process steps and parameters are pre-
programmed in an `activity matrix´ (Fig.  3B). Overall, the automated TCT Process can be 
summarized as follows: T cells, enriched from patient-derived peripheral blood 
mononuclear cells (PBMC) will be activated, lentivirally transduced and expanded. During 
the latter step media will be regularly exchanged. After twelve days, the cellular product 
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will be formulated, harvested and if required frozen. The whole manufacture procedure 
can be closely monitored by analyzing process parameters such as pH and glucose 
concentration as well as product characteristics including cellular composition, T cell 
phenotype and transduction efficiency. 
 
Fig.  3 Technical description of tubing set and `activity matrix´ of the TCT Process. (A) The single-
use disposable tubing set TS520 comprises a pump tubing, a separation column and a cultivation chamber. 
(B) Before starting the process, the incoming product as well as later on reagents, lentiviral particle and 
media was sterile welded onto the closed tubing set. Numbers are indicating valves which are controlled 
according to the pre-programmed `activity matrix´ which defines the sequence of work steps and respective 
process parameters. (A) adapted from TS520 user manual; (B) unpublished data Miltenyi Biotec. 
A successful process for the manufacturing of ATMPs can be assessed on the basis of 
following parameters: I) robustness, II) reproducibility, III) scalability, IV) cost efficiency 
and V) fulfillment of regulatory specifications [66]. A major technical challenge, however, 
represents the heterogeneity of the starting material. Thus, especially exhausted [72-74] 
of heavily pre-treated patient material exhibits strong differences regarding cellular 
composition and phenotypical characteristics. In this context, the use of defined reagents 
and cytokine combinations are of utmost importance to generate a homogenous cell 
product for the clinical use. The combination of IL-7 and IL-15 specifically supports the 
differentiation and maintenance of defined memory T cells [75]. Berger et al. [76] in 
accordance with Wang et al. [77] demonstrated that particularly central memory T cells 
(TCM) persisted long-term after injection and thus maintained a potent T cell effector 
function. However, not only culture conditions but also initial process parameters might 
Introduction 
  
9 
 
impact both production and safety of the final product. Thus, the enrichment and genetic 
modification of malignant B cells and the subsequent reinfusion back into the patient must 
be prevented in all cases.  
Introduction 
  
10 
 
1.3 Solid tumors: A particular challenge for CAR T cell 
therapies 
The pathophysiological characteristics of solid tumors represent an additional challenge 
for cellular therapies. Accordingly, T cell activation as well as sustaining an activated level 
is heavily impeded in a tumor microenvironment not seldom characterized by hypoxia, 
acidic pH or nutrient deficiency [49, 78]. Furthermore, immune suppressor cells including 
regulatory T cells (Treg), myeloid-derived suppressor cells (MDSC) or immature dendritic 
cells are generally overrepresented in the inhospitable environment. Also several 
inhibitory pathways on solid tumors as well as T cell associated inhibitory mechanisms 
are upregulated [79, 80]. 
Currently, in contrast to B cell malignancies, the clinical potential of CAR T cell therapies 
in a solid tumor setting is disappointing. The issues range from a shortage of known 
`tumor-only´ antigens, a highly immunosuppressive tumor-microenvironment and an 
impeded tumor infiltration [49, 81]. While the two latter aspects primarily affect functionality, 
the lack of available antigens is a serious safety problem. At present all CAR formats 
target antigens that are highly expressed on tumorigenic cells but also, albeit to a lesser 
extent, on other tissues [82-84]. Nevertheless, the risk of on-target/off-tumor reactions is 
omnipresent.  
There are several strategies and technologies to circumvent at least defined problems for 
CAR T cell therapies in a solid tumor setting. Lanitis et al. [85], for instance, demonstrated 
the possibility to physically separate `signal 1´ (CD3) and `signal 2´ (CD28) on two CAR 
constructs directed against different target antigens. In this case, T cells only persisted 
and lysed tumor cells when both antigens were simultaneously expressed on the tumor. 
This AND CAR approach was further refined by Roybal et al. [86] who designed a very 
elegant synNotch receptor-based solution. A constitutively expressed CAR 1 is inducing 
the expression of CAR 2 upon target binding. The latter kills the tumor cell. Alternative 
safety approaches could be used, inter alia, enzyme-sensitive peptides that block the scFv 
until the tumor microenvironment-specific protease cleaves the linker [87]. 
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While there are already several technologies focusing on safety, comparatively few 
approaches were published to improve efficacy of CAR T cells. Nevertheless, pioneer 
work was done by Melero et al. [88, 89]. They proved both that systemically administered 
anti-4-1BB antibodies and/or 4-1BBL engineered tumor cells can be used to induce a 
boosted T cell immunity. Stephan et al. [90] confirmed the “great value of using effective 
costimulation to boost anti-tumor T cell activities”, however, they also referred to the 
inherent danger of an undirected T cell activation. To circumvent this issue, they endowed 
tumor-directed T cells with either CD80 or 4-1BBL and thus systemically enhanced the T 
cell effector function. Finally, Zhao et al. [50] transferred this technique into engineered 
T cells and demonstrated the superiority of CAR T cells receiving agonistic co-stimulation. 
Another promising option to ameliorate the potential of ACT approaches including CAR 
T cells, T cell receptor (TCR)-modified T cells or TILs, not only in solid tumor settings but 
also beyond, might be the use of co-expressed chimeric co-stimulatory receptors (CCRs). 
These artificial receptors comprise an extracellular binding moiety and spacer as well as 
defined intracellular signaling domains which differ from conventional CAR designs. CCR 
expressing T cells do not proliferate nor induce any cytolytic activity upon target cell 
binding, however, are capable of boosting a simultaneously activated CAR T cell response 
which results in an enhanced release of inflammatory cytokines and increased cytolytic 
potential. Furthermore, it is conceivable that activated CCRs are able to ensure survival 
and persistency of engineered T cells. Thus, it is not only possible to enhance the potential 
of CAR T cells with this tool but also to control the co-stimulatory intensity which offers an 
option to avert an excessive release of cytokines that might cause a life-threatening 
cytokine storm [41, 91-93]. In this context, CCRs targeting artificial antigens such as 
dextran or biotin would provide a valuable tool. Consequently, the boost strength could be 
fine-tuned by the dose as well as the injection interval of those antigens. In addition, 
combinatorial approaches of CARs with low affinity scFvs that spare low level target 
antigen expression in basal tissues and CCRs used to boost their restricted cytolytic 
potential opens up a wide range of clinical therapies. Therapeutically there are 
fundamentally two approaches: I) CAR and CCR, co-expressed on T cells, are both 
directed against different antigens co-expressed on one tumor cell (cis approach) or II) 
the CAR specifically binds a tumor-associated antigen while the CCR recognizes a non-
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tumor-associated antigen and induces the boost (trans approach). The general CCR 
concept is exemplified in Fig.  4. 
 
Fig.  4 CCR concept to ameliorate CAR T cell potency. T cells expressing a CAR with a low affinity 
scFv spare low level target antigen expression in basal tissues and thus reduces the risk of on-target/off-
tumor reactions. (A) However, CAR T cells show only modest functionality. (B) CCRs on their own do not 
induce any T cell activation due to the incorporation of defined intracellular domains. (C) A simultaneous 
activation of both CAR and CCR results in a boosted immune response. This boosting effect can be induced 
in cis, by activating the CCR via a tumor-associated antigen, or in trans, by redirecting the CCR to a non-
tumor-associated antigen. 
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1.4  Objectives 
CAR expressing T cells, re-directed to specifically recognize and eliminate malignant cells, 
have demonstrated their efficacy in several clinical trials and thus greatly increased the 
scope and potency of ACT. However, especially in the context of anti-CD19 CAR T cell 
therapies for the treatment of B cell malignancies, a significant number of patients relapse 
due to antigen loss. Therefore, this study initially focused on the development of a novel 
CD20-directed CAR, intended to be used in a clinical setting for the treatment of 
lymphoma as well as melanoma patients. In addition, we focused on additional 
requirements facilitating a further dissemination of CAR T cells including a robust 
manufacturing process and technologies supposed to translate the medical success of 
CARs into solid tumor settings.  
Project 1 Generation and evaluation of CD20-directed CAR T cells 
Primary goals included the design of a novel CD20-directed CAR, the production of viral 
particles and the testing of herewith engineered T cells. For this purpose, molecular 
biological methods and transgenic cell lines were established. Furthermore, protocols and 
assays were developed to deeply analyze the potential of CAR T cells in vitro as well as 
in vivo and to finally translate our findings from bench to bedside. 
Project 2 Automated manufacturing of engineered T cells 
In this subproject, a closed cGMP-compliant, automated T Cell Transduction (TCT) 
Process on the CliniMACS Prodigy platform was established. Both robustness and 
reproducibility of the manufacturing process was verified with patient material.  
Project 3 Assessing a boosting concept 
In addition, we developed novel CCRs, tools which are meant to ameliorate the efficacy 
of CAR T cells especially in a solid tumor setting. Thus, this work provided protocols and 
tools to generate CAR as well as CCR co-expressing T cells and demonstrated that 
defined co-stimulatory ligands are required to enhance both killing potential and cytokine 
release upon a simultaneous activation of CAR and CCR.  
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2  Material and Methods 
 
2.1  Material 
2.1.1  Chemicals 
AB Serum, human    Gemini Bio Products (West Sacramento, USA) 
Accutase     Merck (Darmstadt, D) 
Acetic acid     Sigma-Aldrich (St. Louis, USA) 
Agarose     Invitrogen (Carlsbad, USA) 
Ampicillin     Roche (Basel, CH) 
ATP (10 mM)    Thermo Fisher Scientific (Waltham, USA)  
Bovine Serum Albumin (BSA)  Sigma-Aldrich (St. Louis, USA) 
CliniMACS CD4 Reagent   Miltenyi Biotec (Bergisch Gladbach, D) 
CliniMACS CD8 Reagent   Miltenyi Biotec (Bergisch Gladbach, D) 
CliniMACS PBS/EDTA   Miltenyi Biotec (Bergisch Gladbach, D) 
Composol     Fresenius (Bad Homburg, D) 
Dimethyl sulfoxide (DMSO)  Sigma-Aldrich (St. Louis, USA) 
Disodium hydrogenorthophosphate Merck (Darmstadt, D) 
DMEM     Miltenyi Biotec (Bergisch Gladbach, D) 
DNA Ladder 1 Kb plus   Thermo Fisher Scientific (Waltham, USA) 
Phosphate Buffered Saline (PBS)  Thermo Fisher Scientific (Waltham, USA) 
Dithiothreitol (DTT)    Sigma-Aldrich (St. Louis, USA) 
Erythrosine B    Sigma-Aldrich (St. Louis, USA) 
Ethylenediaminetetraacetate (EDTA) Carl Roth (Karlsruhe, D) 
Ethidium bromide 0,025%   Carl Roth (Karlsruhe, D) 
Fetal calf serum (FCS)   Merck (Darmstadt, D) 
Human Serum Albumin (HSA)  Grifols (Barcelona, ES) 
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IL-2, human recombinant   Miltenyi Biotec (Bergisch Gladbach, D) 
IL-7, human recombinant   Miltenyi Biotec (Bergisch Gladbach, D) 
IL-15, human recombinant   Miltenyi Biotec (Bergisch Gladbach, D) 
Ionomycin     Sigma-Aldrich (St. Louis, USA)  
Kanamycin sulfate    Sigma-Aldrich (St. Louis, USA) 
LB agar (Luria/Miller)   Carl Roth (Karlsruhe, D) 
LB growth medium    Invitrogen (Carlsbad, USA) 
L-Glutamine     Lonza (Basel, CH) 
MACSfectin Reagent   Miltenyi Biotec (Bergisch Gladbach, D) 
MACS GMP T Cell TransAct  Miltenyi Biotec (Bergisch Gladbach, D) 
Pancoll human    PAN Biotech (Aidenbach, D) 
Penicillin-Streptomycin (P/S)  Lonza (Basel, CH) 
Phorbol myristate acetate (PMA)  Sigma-Aldrich (St. Louis, USA) 
Polyethylenimine, MW 25,000 (PEI) Polysciences (Warrington, USA)   
Potassium chloride    Merck (Darmstadt, D) 
Potassium dihydrogen phosphate  Merck (Darmstadt, D) 
RetroNectin     Takara (Kusatsu, J) 
RPMI 1640     Biowest (Nuaillé, F) 
SOC-Medium    NEB (Ipswitch, USA) 
Sodium chloride (NaCl)   Merck (Darmstadt, D) 
Sodium bicarbonate    Merck (Darmstadt, D) 
Sodium butyrate    Sigma-Aldrich (St. Louis, USA) 
T Cell TransAct, human   Miltenyi Biotec (Bergisch Gladbach, D) 
TexMACS Medium research grade Miltenyi Biotec (Bergisch Gladbach, D) 
TexMACS GMP Medium   Miltenyi Biotec (Bergisch Gladbach, D) 
Trypsin-EDTA 0,05%   Thermo Fisher Scientific (Waltham, USA) 
Tween-20     Sigma-Aldrich (St. Louis, USA) 
Vetflurane 1000 mg/g   Virbac (Fort Worth, USA) 
XenoLight D-Luciferin-K+ Salt  PerkinElmer (Waltham, USA) 
XenoLight RediJect D-Luciferin Ultra PerkinElmer (Waltham, USA) 
X-Gal      Thermo Fisher Scientific (Waltham, USA) 
Xylencyanol      AppliChem (Darmstadt, D)  
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2.1.2  Buffer, media and supplements 
Agarose gel   1% Agarose 
    1x TAE buffer 
B16-F10 medium  DMEM 
    10% FCS 
CT26.wt medium  RPMI 
    10% FCS   
Freezing medium  FCS 
10% DMSO 
HEK 293-T medium  DMEM 
    10% FCS   
JeKo-1 medium  RPMI 
    10% FCS 
    2 mM L-Glutamin 
Jurkat medium  RPMI 
    10% FCS 
    2 mM L-Glutamin 
LB agar plates  40 g LB agar 
    ad 1 l Aqua dest. 
add either Kanamycin (50 µg/ml) or Ampicillin (100 µg/ml) 
(optional 40 µg/ml X-Gal) to autoclaved, cooled agar and pour 
into 10-cm dishes. 
LB growth medium  25 g LB growth medium 
    ad 1 l Aqua dest. 
add either Kanamycin (50 µg/ml) or Ampicillin (100 µg/ml) to 
autoclaved, cooled medium. 
Mel526 medium  RPMI 
    10% FCS 
    2 mM L-Glutamin 
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NALM6 medium  RPMI 
    10% FCS 
    2 mM L-Glutamin 
PBS 10x pH   80 g NaCl 
14.4 g Na2HPO4 
2.0 g KCl 
2.4 g KH2PO4 
ad 1 l Aqua dest. 
adjust to pH 7.4 
PEB    100 ml PBS 10x 
4 ml 0,5 M EDTA 
5 g BSA 
ad 1 l Aqua dest. 
Raji medium   RPMI 
    10% FCS 
    2 mM L-Glutamin 
SupT1 medium  RPMI 
    10% FCS 
    2 mM L-Glutamin 
TAE buffer 50x  57.1 ml acetic acid 
    18.6 g EDTA 
    ad 1 l with Aqua dest. 
T cell medium  TexMACS 
    12.5 ng/ml IL-7 
    12.5 ng/ml IL-15 
    (optional 200 IU IL-2 instead of IL-7 / IL-15)  
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2.1.3  Restriction endonucleases and buffers 
Restriction endonucleases 
Avr II       NEB (Ipswitch, USA) 
BamH I      NEB (Ipswitch, USA) 
Bbs I       NEB (Ipswitch, USA) 
Bcl I       NEB (Ipswitch, USA) 
Bve I       Thermo Fisher Scientific Waltham, USA) 
EcoR I       NEB (Ipswitch, USA) 
Mlu I       NEB (Ipswitch, USA) 
Nco I       NEB (Ipswitch, USA) 
Nhe I       NEB (Ipswitch, USA) 
Pml I       NEB (Ipswitch, USA) 
Pst I       NEB (Ipswitch, USA) 
Sal I       NEB (Ipswitch, USA) 
Sca I       NEB (Ipswitch, USA) 
 
Buffers 
NEBuffer 1.1      NEB (Ipswitch, USA) 
NEBuffer 2.1      NEB (Ipswitch, USA) 
NEBuffer 3.1      NEB (Ipswitch, USA) 
Buffer O      ThermoFisher Scientific Waltham, USA) 
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2.1.4  Oligonucleotides 
All oligonucleotides were synthesized at Metabion (Planegg/Steinkirchen, D) or GATC 
(Konstanz, D). 
gRNA 19.2   5’- CACCCCCCATGGAAGTCAGGCCCG -3´ 
3’-   GGGGTACCTTCAGTCCGGGCCAAA -5’ 
gRNA 20.4  5’- CACCCACGCAAAGCTTCTTCATGA -3´  
3’-   GTGCGTTTCGAAGAAGTACTCAAA -5’    
BriD-007 CGATGGGCTGTGGCCAATAG Sequencing 
 
pDoc-117 TGCGTGAAATCATCAGGGTGTC Sequencing 
 
pDoc-118 TTTCTTCTTGGCTCGGCGGCAAGG Sequencing 
pDoc-119 ACAGCAGCAGCACGCCACAAGTTC Sequencing 
pDoc-129 GCTTCAGCAGCGAGAAGTTG Sequencing 
 
pDoc-130 GAACTTGTGGCGTGCTGCTG Sequencing 
 
pDoc-148 AGTTCCGCTTGGTCTCATGC Sequencing 
pDoc-149 TCCTGCTGTCGCTGGTCATC Sequencing 
pDoc-150 CATGGCCCTTCCAGTAGCTC Sequencing 
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2.1.5  Plasmids 
Tab. 1 Generated and/or used plasmids 
Construct Description Reference 
#1455 retroviral anti-CD20 CAR H. Abken (ZMMK Cologne) 
Cas9/gRNA Cas9/guide RNA encoding plasmid Cong et al. 2013 [94] 
CD20_1 lentiviral anti-CD20 (vh/vl) CAR derived from #1455 this work 
CD20_2 lentiviral anti-CD20 CAR vl/vh IgG1 Spacer, PPGK Miltenyi Biotec 
CD20_3 lentiviral anti-CD20 CAR vl/vh IgG1 Spacer, PEF-1 Miltenyi Biotec 
CD20_4 lentiviral anti-CD20 CAR vl/vh CD8 Spacer, PEF-1 Miltenyi Biotec 
CD20_5 lentiviral anti-CD20 CAR vh/vl CD8 Spacer, PEF-1 Miltenyi Biotec 
CD20_6 lentiviral anti-CD20 CCR 4-1BB_4-1BB IgG1 Hinge_CH2_CD3 this work 
CD20_7 lentiviral anti-CD20 CCR 4-1BB_CD3 IgG1 Hinge_CH2_CD3 this work 
CD20_8 lentiviral anti-CD20 CCR CD3_CD3 IgG1 Hinge_CH2_CD3 this work 
CD20_9 lentiviral anti-CD20 CCR CD28_4-1BB IgG1 Hinge_CH2_CD3 this work 
CD20_10 lentiviral anti-CD20 CCR CD28_CD3 IgG1 Hinge_CH2_CD3 this work 
CD20_11 lentiviral anti-CD20 CCR 4-1BB IgG1 Hinge_CH2_CD3 this work 
CD20_12 lentiviral anti-CD20 CCR CD28_CD28 IgG1 Hinge_CH2_CD3 this work 
CD20_13 lentiviral anti-CD20 CCR CD28 IgG1 Hinge_CH2_CD3 this work 
CD20_14 lentiviral anti-CD20 CCR 4-1BB_4-1BB CD8 Spacer this work 
CD20_15 lentiviral anti-CD20 CCR 4-1BB CD8 Spacer this work 
CD20_16 lentiviral anti-CD20 CCR CD28_4-1BB CD8 Spacer this work 
CD20_17 lentiviral anti-CD20 CCR 4-1BB_4-1BB IgG4 Spacer long this work 
CSPG4_1 retroviral aCSPG4 CAR H. Abken (ZMMK Cologne) 
CSPG4_2 lentiviral aCSPG4 CAR 225.28s IgG4 Hinge_CH2_CH3 this work 
CSPG4_3 lentiviral aCSPG4 CAR 225.28s IgG4 Hinge_CH3 this work 
CSPG4_4 lentiviral aCSPG4 CAR 225.28s IgG4 Hinge this work 
CSPG4_5 lentiviral aCSPG4 CAR TP61.5 IgG4 Hinge_CH2_CH3 this work 
CSPG4_6 lentiviral aCSPG4 CAR TP61.5 IgG4 Hinge_CH3 this work 
CSPG4_7 lentiviral aCSPG4 CAR TP61.5 IgG4 Hinge this work 
CSPG4_8 lentiviral aCSPG4 CAR 763.74 IgG4 Hinge_CH2_CH3 this work 
CSPG4_9 lentiviral aCSPG4 CAR 763.74 IgG4 Hinge_CH3 this work 
CSPG4_10 lentiviral aCSPG4 CAR 763.74 IgG4 Hinge this work 
CSPG4_11 lentiviral aCSPG4 CAR 763.74 IgG4 CD8 Spacer this work 
DC_1 lentiviral plasmid, combination of CD20_14 & CSPG_2 this work 
DC_2 lentiviral plasmid, combination of CD20_17 & CSPG_2 this work 
Doc_1 lentiviral plasmid encoding firefly luciferase_eGFP this work 
Doc_2 lentiviral plasmid encoding hCD20_eGFP this work 
GFP lentiviral GFP encoding construct Lentigen 
MB_001 lentiviral CAR library scFv IgG4 Hinge_CH2_CH3 this work 
MB_002 lentiviral CAR library scFv IgG4 Hinge_CH3 this work 
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Construct Description Reference 
MB_003 lentiviral CAR library scFv IgG4 Hinge this work 
MB_004 lentiviral CAR library scFv hCD8 this work 
MB_005 lentiviral CAR library endogenous domains (CD20_2 derived) this work 
MB_006 lentiviral CAR library endogenous domains (CD20_4 derived) this work 
pCMVdR8.74 helper plasmid, HIV-1-derived gag pol tat rev  
pCMVR8.74 was a gift from 
Didier Trono (Addgene 
plasmid # 22036) 
pHit60 helper plasmid encoding gag pol Soneoka et al. 1995 [95] 
pMDG-2 helper plasmid, VSV-G 
pMD2.G was a gift from 
Didier Trono (Addgene 
plasmid # 12259) 
CG1711 self-inactivating lentiviral vector 
Cell Genesis Inc.; South San 
Francisco (USA) 
 
2.1.6  Kits 
Amaxa Cell line Nucleofector Kit V Lonza (Basel, CH) 
Anti-Biotin MultiSort Kit   Miltenyi Biotec (Bergisch Gladbach, D) 
B cell isolation Kit II, human  Miltenyi Biotec (Bergisch Gladbach, D) 
Cell line Nucleofector Kit V   Lonza (Basel, CH) 
CellTrace Violet Cell Proliferation Kit Thermo Fisher Scientific (Waltham, USA) 
EndoFree PlasmidMaxiKit   Qiagen (Hilden, D) 
MACSPlex Cytokine 12 Kit, human Miltenyi Biotec (Bergisch Gladbach, D) 
MACS GMP TransAct CD3/CD28 Kit Miltenyi Biotec (Bergisch Gladbach, D) 
NucleoSpin Gel and PCR Clean-Up Macherey-Nagel (Düren, D) 
NucleoSpin Plasmid EasyPure  Macherey-Nagel (Düren, D) 
Pan T cell Isolation Kit, human  Miltenyi Biotec (Bergisch Gladbach, D) 
Plasmid Maxi Kit    Qiagen (Hilden, D) 
Rapid DNA Dephos & Ligation Kit  Sigma-Aldrich (St. Louis, USA) 
ZymoPureTM Plasmid Midiprep Kit Zymo research (Irvine, USA)   
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2.1.7  Antibodies 
Tab. 2 Antibodies and staining reagents 
Antibody clone conjugate Producer 
7-AAD --- --- Miltenyi Biotec (Bergisch Gladbach, D) 
Biotin --- MB / APC / VB Miltenyi Biotec (Bergisch Gladbach, D) 
CD20 CAR peptide --- PE product in development (Miltenyi Biotec, D) 
CD3 
BW264/56 & 
REA613 
FITC Miltenyi Biotec (Bergisch Gladbach, D) 
CD4 VIT4 PE / VG Miltenyi Biotec (Bergisch Gladbach, D) 
CD8 BW138/80 
VB / APC-
Vio770 
Miltenyi Biotec (Bergisch Gladbach, D) 
CD14 TÜK4 APC Miltenyi Biotec (Bergisch Gladbach, D) 
CD16 REA423 FITC / PE Miltenyi Biotec (Bergisch Gladbach, D) 
CD19 LT19 VB / MB Miltenyi Biotec (Bergisch Gladbach, D) 
CD20 LT20 APC / Biotin Miltenyi Biotec (Bergisch Gladbach, D) 
CD25 4E3 PE Miltenyi Biotec (Bergisch Gladbach, D) 
CD45 REA747 VB Miltenyi Biotec (Bergisch Gladbach, D) 
CD45RO REA611 PE-Vio770 Miltenyi Biotec (Bergisch Gladbach, D) 
CD56 REA196 PE Miltenyi Biotec (Bergisch Gladbach, D) 
CD62L 145/15 VB Miltenyi Biotec (Bergisch Gladbach, D) 
CD69 FN50 APC Miltenyi Biotec (Bergisch Gladbach, D) 
CD95 DX2 APC Miltenyi Biotec (Bergisch Gladbach, D) 
CD271 (LNGFR) ME20.4-1.H4 APC Miltenyi Biotec (Bergisch Gladbach, D) 
CSPG4 EP-1 APC / VB Miltenyi Biotec (Bergisch Gladbach, D) 
EGFR EGFR.1 (RUO) PE BD (Franklin Lakes, USA) 
IgG Fc polyclonal Biotin Thermo Fisher Scientific (Waltham, USA) 
PE --- MB Miltenyi Biotec (Bergisch Gladbach, D) 
PI --- --- Miltenyi Biotec (Bergisch Gladbach, D) 
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2.1.8  Cell lines 
Tab. 3 Generated and/or used cell lines 
Cell line Reference 
B16-F10 FFluc_eGFP this work 
CT26.wt FFluc_eGFP this work 
HEK 293-T ATCC CRL-3216 
JeKo-1 ATCC CRL-3006 
JeKo-1FFluc_eGFP this work 
JeKo-1FFluc_eGFP CD19 ko this work 
JeKo-1FFluc_eGFP CD20 ko this work 
JeKo-1FFluc_eGFP CD19/CD20 ko this work 
Jurkat ATCC TIB-152 
Mel526 RRID:CVCL_8051 
Mel526FFluc_eGFP this work 
Mel526CD20_FFluc_eGFP this work 
NALM6 ATCC CRL-3273 
NALM6FFluc_eGFP this work 
Raji ATCC CCL-86 
RajiFFluc_eGFP this work 
RajiFFluc Lentigen 
SupT1 ATCC CRL-1942 
 
2.1.9  Consumables, devices and software 
96/48/24/12-well flat/round bottom cell 
culture plates (non) tissue culture treated 
Corning (New York, USA) 
75/175 cm2 cell culture flasks  Sigma-Aldrich (St. Louis, USA) 
96-well black well plates Miltenyi Biotec (Bergisch Gladbach, D) 
10 cm culture dish 
ABT 220-4m 
Sarstedt (Nümbrecht, D)  
Kern+Sohn GmbH (Balingen, D) 
ACCU-CHECK Aviva 
BD 115 
Roche (Basel, CH) 
Binder (Tuttlingen, D) 
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BioRad Power Pac 300 Bio Rad Bio-Rad (Hercules, USA) 
BP 3100S Sartorius (Göttingen, D) 
Cell Strainer 40 µm and 70 μm  BD (Franklin Lakes, USA)  
Cell culture hood, Hera Safe KS  Thermo Fischer Scientific (Waltham, USA)  
Centrifuge 4515R  Eppendorf (Hamburg, D) 
Centrifuge, Multifuge 4KR  Thermo Fischer Scientific (Waltham, USA) 
Centrifuge, Eppendorf 5415D  Eppendorf (Hamburg, D) 
Centrifuge, Multifuge X3R  Heraeus Instruments (Hanau, D)  
Certomat BS-1 
CliniMACS Prodigy 
CliniMACS Prodigy TCT application V.1 
Clone Manager 9 Professional Edition 
Sartorius (Göttingen, D) 
Miltenyi Biotec (Bergisch Gladbach, D) 
Miltenyi Biotec (Bergisch Gladbach, D) 
Scientific & Educational Software (Denver, 
USA) 
CO2 Incubator, Hera Cell  Thermo Fischer Scientific (Waltham, USA) 
Conical bottom tubes, 50 ml, 15 ml 
Filter Unit 0,45 µm 
BD (Franklin Lakes, USA)  
Merck (Darmstadt, D) 
Gene Pulser II System Bio Rad Bio-Rad (Hercules, USA) 
Graph Pad Prism 7.0  GraphPad Software, Inc. (La Jolla, USA)  
Hemocytometer 
Hera Safe KS 
IncuCyte 
IVIS Lumina III 
NanoEntek (Seoul, Korea) 
Thermo Fischer Scientific (Waltham, USA) 
Essen Bioscience (Ann Arbor, USA) 
PerkinElmer (Waltham, USA) 
Julabo 5 
Living Image 
Julabo Labortechnik (Seelbach, D) 
PerkinElmer (Waltham, USA) 
MACSplex Filter plates Miltenyi Biotec (Bergisch Gladbach, D) 
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MACSQuant Analyzer 10  Miltenyi Biotec (Bergisch Gladbach, D) 
MACSQuantify, version 2.5 – 2.10 Miltenyi Biotec (Bergisch Gladbach, D) 
MACS Separator (Octo, Quadro)  Miltenyi Biotec (Bergisch Gladbach, D) 
MACS separation columns (MS, LS, LD)  Miltenyi Biotec (Bergisch Gladbach, D) 
Microcentrifuge tubes  STARLAB (Hamburg, D)  
Microscope, Leica DM IL LED  Leica Microsystems (Wetzlar, D)  
Microsoft Office Professional 2010 - 2016  Microsoft Coorporation (Redmond, USA)  
Mr. Frosty 
NALGENE Cryogenic vials  
Thermo Fischer Scientific (Waltham, USA) 
Thermo Fischer Scientific (Waltham, USA) 
NanoDrop ND-1000 Spectrophotometer Thermo Fischer Scientific (Waltham, USA) 
NEB 5-alpha Competent E. coli 
Nuaire class II biological safety cabinet 
Nucleofector 2b Device 
NEB (Ipswitch, USA) 
Nuaire (Plymouth, USA) 
Lonza (Basel, CH) 
Orbital shaker Titramax 100  Heidolph (Schwabach, D) 
pH-Meter, pH-Meter 765 Calimatic  
pH Test Strips (MColorpHast, pH 6.5-10) 
Elektronische Messgeräte, (Berlin, D) 
Merck (Darmstadt, D) 
Red Blood Cell Lysis Solution (10x) 
Reax top 
Miltenyi Biotec (Bergisch Gladbach, D) 
Heidolph (Schwabach, D) 
Surgical Scalpel  Aesculap AG (Tuttlingen D)  
Sysmex XP-300 Sysmex Deutschlang, (Norderstedt, D) 
Thermomixer comfort 
Transfer bag 
TS520 tubing set 
TSCD II 
Eppendorf (Hamburg, D) 
Terumo (Tokio, J) 
Miltenyi Biotec (Bergisch Gladbach, D) 
Terumo (Tokio, J) 
VICTOR X4 2030 Multilabel Reader PerkinElmer (Waltham, USA) 
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XGI-8 Anesthesia System PerkinElmer (Waltham, USA) 
 
Additional consumables including pipettes, pipet tips, serological pipets, different reaction 
tubes or syringes were mainly ordered at Eppendorf (Hamburg, D), PeQlab (Erlangen, D), 
Greiner bio-one (Kremsmünster, A), Mettler-Toledo (Gießen, D), Sarstedt (Nümbrecht, D) 
STARLAB (Hamburg, D), BD (Franklin Lakes, USA) and Braun (Bethlehem, USA). 
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2.2  Molecular biological methods 
2.2.1  Standard methods and explanations 
All molecular biological methods not described in detail were performed as described by 
Green and Sambrock [96]. Unless mentioned to the contrary, kits were used according to 
the manufacturer´s protocol. 
2.2.2  Molecular cloning 
In silico designed DNA-elements were human codon optimized and synthesized at 
GenScript (Piscataway, USA) or ATUM (Newark, USA). Enzymatically digested DNA 
fragments were separated via gel electrophoresis (Cap. 2.2.1) and extracted using the 
NucleoSpin Gel and PCR Clean-up-Kit. If required, DNA fragments were 
dephosphorylated using the Rapid DNA Dephos and Ligation Kit and subsequently cloned 
into the intended plasmid considering the molar ratio of backbone to insert using the Rapid 
DNA Dephos and Ligation Kit as exemplarily shown in Tab. 4. 
Tab. 4 Conventional cloning protocol  
ratio backbone : insert µl    
  x 50 ng backbone  
1:3 x 150 ng/F insert F = bp backbone / bp insert 
1:5 x 250 ng/F insert  
  ad 8 Aqua dest.  
  2 DNA Dilution Buffer  
  10 DNA Ligation Buffer  
    T4 DNA Ligase  
  
Incubation for 10 min at RT. 
Generally, scFv sequences as well as co-stimulatory- and signaling domain-encoding 
DNA elements were cloned following a high-throughput protocol (Tab. 5) using Bve I, a 
Type IIS restriction enzyme [97]. 
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Tab. 5 High-throughput cloning protocol 
 µl 
 backbone 2 
insert 1 2 
insert 2 (optional) 2 
Buffer O 10x  5 
 Oligonucleotides 50x 1 
Bve I 2 
DTT 10 mM  5 
ATP 10 mM  2.5 
T4 DNA Ligase 2 
Aqua dest. ad 50 
 
Incubation for 5 h at 37°C. 
2.2.3  Transformation of chemically competent E.coli 
1 ng plasmid or rather 5 µl of the ligation preparation (Cap. 2.2.2) were added to freshly 
thawed NEB 5-alpha competent E. coli, carefully mixed and incubated for 30 min on ice. 
Transformation was achieved via heat shock at 42°C for 30 s. Subsequently, cells were 
placed on ice for 5 min, before 250 µl SOC-Medium was added into the mixture and 
incubated for 60 min at 37°C with 250 rpm. The mixture was spread onto LB-Agar 
selection plates with either 50 µg/ml Kanamycin or 100 µg/ml Ampicillin (optional 40 µg/ml 
X-Gal, respectively). Plates were incubated at 37°C overnight. 
2.2.4  Amplification, isolation and quantification of plasmids 
After transformation (Cap. 2.2.3), plasmid DNA was amplified in bacteria due to 
prokaryotic DNA replication mechanisms and subsequently purified out of the E. coli. 
Grown colonies were picked from the LB-Agar selection plate and transferred into 2 ml LB 
growth media containing antibiotics (50 µg/ml Kanamycin or 100 µg/ml Ampicillin). The 
liquid culture was incubated overnight at 37°C in a shaking incubator (300 rpm). Plasmid 
DNA was isolated by alkaline hydrolysis using the miniprep kit NucleoSpin Plasmid.  
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For a higher yield, which was required for plasmids used for lentiviral vector production, a 
2 ml pre-culture was used after 6-8 h to inoculate either 50 ml (midiprep) or 200 ml 
(maxiprep) LB growth media supplemented with either 50 µg/ml Kanamycin or 100 µg/ml 
Ampicillin. Bacterial culture was incubated overnight at 37°C with 300 rpm. The 
ZymoPURE Plasmid Midiprep kit was used to purify up to 300 µg endotoxin-free plasmid 
DNA. Maxipreps were performed with the EndoFree Plasmid Maxi kit enabling the 
isolation of up to 500 µg plasmid DNA. 
Based on the characteristic absorption maximum of DNA at 260 nm, all DNA 
concentrations and purities (OD260/OD280) were determined using the NanoDrop ND-1000 
Spectrophotometer. 
2.2.5  Plasmid sequence verification 
Successive cloning steps were analyzed via hydrolytic cleavage catalyzed by restriction 
endonucleases (Tab. 6) followed by gel electrophoresis (Cap. 2.2.1).  
Tab. 6 Restriction endonuclease digestion protocol 
 µl 
plasmid DNA 7  
buffer 2 
endonuclease 10 U/µl 1 
Aqua dest.  ad 20 µl 
 
Incubation for 1 h at 37°C. 
All final constructs were sequenced at GATC (Konstanz, D) using appropriate sequencing 
primers (Cap. 2.1.4). Sequences were analyzed using Clone Manager. 
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2.3  Cell biological methods 
Unless mentioned to the contrary, kits were used according to the manufacturer´s protocol. 
2.3.1  PBMC preparation 
Buffy coats and leukapheresis products were obtained from the university hospital in 
Dortmund and Cologne. Each donor used in this study provided written informed consent 
before sample collection in accordance with the declaration of Helsinki. PBMC were 
isolated sterile using Pancoll human and density gradient centrifugation for 35 min at 
445 g with moderate break. 
2.3.2  Isolation, activation and expansion of PAN T cells 
PAN T cells were isolated from freshly isolated or frozen PBMC using the human PAN 
T cell isolation Kit. 
T cells were activated in TexMACS supplemented with either 12.5 ng/ml recombinant 
human IL-7 and 12.5 ng/ml recombinant human IL-15 or 200 IU IL-2 with MACS GMP T 
Cell TransAct with a titer of 1:17.5 or T Cell TransAct, human with a titer of 1:100. For this 
purpose, 1E6 T cells per cm2 were cultured in 1 ml medium for 72 h at 37°C and 5% CO2 
atmosphere before the stimulation reagent was removed. From then onwards T cells were 
cultured in 24-well plates in 2 ml TexMACS supplemented with either 12.5 ng/ml 
recombinant human IL-7 and 12.5 ng/ml recombinant human IL-15 or 200 IU IL-2. T cells 
were splitted 1:2 every other day. 
2.3.3  Isolation and cultivation of B cells 
B cells were isolated from frozen PBMC using the B cell isolation Kit II, human and cultured 
overnight in TexMACS. 
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2.3.4  Cultivation of cell lines 
All cell lines were cultured in an appropriate media (Cap. 2.1.2) at 37°C and 5% CO2 
atmosphere. Cell lines were splitted twice every week. For this purpose, adherent cell 
lines were detached using Trypsin-EDTA 0,05% or Accutase (melanoma cell lines) for 5 
min at 37°C. 
2.3.5  Freezing and thawing of cells 
For freezing cells were centrifuged at 300 g, resuspended in freezing medium (Cap. 2.1.2) 
and subsequently stored at -70°C using a Mr. Frosty freezing container. After 24 h cells 
were transferred into liquid nitrogen for long term storage.  
Cells were thawed at 37°C, immediately washed in their culture medium (Cap. 2.1.2) and 
appropriately plated. 
2.3.6  Production of lentiviral particles 
Vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped lentiviral vectors were 
produced using HEK 293-T cells. 1.6E7 cells were seeded in 20 ml medium (Cap. 2.1.2) 
in a T175 flask 20 h prior to transfection. 3.15 µg VSV-G encoding plasmid pMDG-2, 
19.37 µg gag/pol/rev encoding plasmid pCMVdR8.74 and 12.59 µg transfer vector 
plasmid were diluted in 3.5 ml DMEM without additives and mixed with 3.5 ml DMEM 
supplemented with 280 µl PEI (1 mg/ml). The transfection mixture was incubated for 
20 min at RT. HEK 293-T medium was completely removed from the cells and replaced 
with 16 ml DMEM without additives. Subsequently, the transfection mixture was carefully 
added to the cells. After 4 - 6 h 2.5 ml FCS were added and cultured for 24 h before 520 µl 
sodium butyrate (500 mM) was additionally added. 48 h after transfection, supernatant 
was collected, sterile filtrated and concentrated at 4°C for 24 h at 5350 g. Pelleted lentiviral 
particles were diluted in PBS and freshly used or stored at -70°C. 
If required, titers of the lentiviral particles were determined. For this purpose, either SupT1 
or Jurkat cells were transduced with an increasing volume of lentiviral particles. After 72 
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h the specific transgenic expression was analyzed via flow cytometry (Cap. 2.3.7) and 
titers were calculated based on the frequency and quantity of transgenic cells. 
2.3.7 Cell surface marker staining and detection via flow 
cytometry 
At least 1E4 cells were harvested and resuspended in PEB. Cells were stained in 
appropriate titers with conjugated antibodies or peptides for 10 min at 4°C. Subsequently, 
PEB was added to the cells, centrifuged for 5 min at 300 g and resuspended in fresh PEB. 
If required cells were additionally stained with secondary antibodies, washed and 
resuspended as described above. 
Stained cells were measured using the MACSQuant Analyzer 10. 
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2.4  Gene-engineering 
Unless mentioned to the contrary, kits were used according to the manufacturer´s protocol. 
2.4.1  T cell transduction 
T cells were transduced 24 - 48 h after activation (Cap. 2.3.2) with fresh or frozen, carefully 
resuspended VSV-G pseudotyped lentiviral particles.  
2.4.2  Automated T Cell Transduction Process 
Apel et al. [98] briefly summarized all relevant technical characteristics of the TCT Process 
on the CliniMACS Prodigy. 
Initially, a single-use disposable tubing set TS520 was primed with CliniMACS PBS/EDTA 
supplemented with 0.5% HSA. According to the pre-defined `activity matrix´, samples 
were stained with CliniMACS CD4 Reagent and CliniMACS CD8 Reagent for 30 min at 4-
8°C and subsequently enriched via the integrated separation column for magnetic 
selection. Up to 1E8 enriched cells, eluted in TexMACS GMP Medium supplemented with 
3% heat-inactivated human AB Serum, 12.5 ng/mL recombinant human IL-7 and 
12.5 ng/mL recombinant human IL-15, were transferred into the cultivation chamber and 
activated with 1 vial of the MACS GMP T Cell TransAct. After 24 h T cells were 
automatically transduced. For this purpose, a 150 ml transfer bag which contains the 
lentiviral particles (formulated in 10 ml culture medium) was sterile welded onto the TS520 
tubing set using the TSCD II. On day three, a culture wash was performed to remove 
surplus stimulation reagent and lentiviral vector. During the following nine days, the 
cultivation volume was subsequently increased to 250 ml whereby a maximum of 180 ml 
medium was exchanged every day. From the sixth day following, cells were cultured 
without human AB serum. On day twelve, cells were formulated and harvested using 
either TexMACS medium or Composol supplemented with 2.84% HSA. The TCT Process 
was closely controlled. Thus, cell numbers and viability were measured frequently using 
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a hemocytometer and erythrosine B staining. Furthermore, pH and glucose concentration 
was monitored using pH Test Strips and a handheld blood sugar meter (ACCU-CHECK 
Aviva). Cellular composition, T cell phenotype as well as transduction efficiency were 
analyzed on day zero (enriched fraction), on day five or six (in-process control) and on 
day twelve (final product) using flow cytometry (Cap. 2.3.7). 
2.4.3  Enrichment of gene-engineered T cells 
If required, CAR-expressing T cells were enriched on day seven after activation (Cap. 
2.3.2) via a co-expressed marker gene (either LNGFR or EGFR). For this purpose, 
gene-modified T cells were harvested, stained with anti-LNGFR-Biotin (titer 1:11) or anti-
EGFR-PE (titer 1:5) for 10 min at 4°C, washed and additionally stained with either anti-
Biotin MultiSort-MB (titer 1:5) or anti-PE-MB for 15 min at 4°C, respectively. For the 
enrichment LS columns and a QuadroMACS Separator were used.  
Co-transduced T cells expressing both transgenes LNGFR and EGFR were enriched 
using the anti-Biotin-MultiSort Kit. Initially LNGFR-positive T cells were enriched as 
described above. After the LS column elution, the anti-Biotin MultiSort-MB was released 
and EGFR-positive cells were enriched as previously described. 
1E6 co-enriched CAR T cells per cm2 cells were seeded in TexMACS supplemented with 
12.5 ng/ml recombinant human IL-7 and 12.5 ng/ml recombinant human IL-15 (or 200 IU 
IL-2) as well as T Cell TransAct, human with a titer of 1:500 for T cell re-activation. After 
48 h at 37°C and 5% CO2 atmosphere stimulation reagent was removed and transgenic 
T cells were expanded in TexMACS supplemented with cytokines (Cap. 2.3.2). 
2.4.4  Generation of firefly luciferase-expressing cell lines 
In this study the following cell lines were genetically modified to express the firefly 
luciferase (FFluc) gene: JeKo-1, Raji, NALM6, Mel526, CT26.wt and B16-F10. Initially, 
1E5 cells were seeded in 1 ml complete growth medium (Cap. 2.1.2) per well in a 48-well 
plate. After 24 h cells were transduced with LV-Doc_1 (Cap. 2.3.6) (100x, Titer 1,4E7 
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TU/ml) with multiplicity of infection (MOI) 4. Cells were cultured for 72 h before cells were 
harvested and seeded (Cap. 2.3.4) at a density of 0.3 cells/well in a 96-well culture plate. 
Cells were cultured for two weeks and then transferred into 12-well culture plates for 
further expansion. Marker expression as well as the transgenic GFP-gene expression 
were analyzed via flow cytometry (Cap. 2.3.7) before several clones of all cell lines were 
frozen (Cap. 2.3.5). 
2.4.5  Generation of CD20-expressing Mel526FFluc_eGFP cells 
Lentiviral particle LV-Doc_2 was generated as previously described (Cap. 2.3.6). Herewith 
1E6 Mel526FFluc_eGFP cells, cultured in complete growth medium in 6-well plates for 24 h, 
were transduced. After 72 h CD20-positive cells were enriched using anti-CD20-
Biotin/anti-Biotin-MB (Cap. 2.3.7), LS columns and a QuadroMACS Separator. Hereafter, 
0.3 cells/well in a 96-well culture plate were seeded and CD20 expressing Mel526FFluc_eGFP 
single cell clones were expanded for two weeks, analyzed (Cap. 2.3.7) and frozen (Cap. 
2.3.5). 
2.4.6  Generation of JeKo-1 knock-out cells 
GuideRNA 19.2 und 20.4 (Cap. 2.1.4) were cloned (Cap. 2.2.2) into the gRNA plasmid 
under the control of a T7-promoter using Bbs I and subsequently amplified in a Midiprep 
(Cap. 2.2.4). 2E6 JeKo-1FFluc_eGFP cells were co-transfected with the 1 µg Cas9 encoding 
plasmid and either 1 µg gRNA 19.2 or 1 µg gRNA 20.4 using the Nucleofector 2b Device 
and the Cell line Nucleofector Kit V. 
Seven days post transfection CD19-positive as well as CD20-positve cells were depleted 
using LD-columns after staining with either anti-CD19-MB or anti-CD20-Biotin/anti-Biotin-
MB (Cap. 2.3.7). Subsequently, 0.3 cells/well in a 96-well culture plate were seeded and 
a single cell expansion was performed. After two weeks, JeKo-1FFluc_eGFP CD19 ko and 
JeKo-1FFluc_eGFP CD20 ko single cell clones were analyzed by flow cytometry (Cap. 2.3.7) 
and frozen (Cap. 2.3.5). 
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Finally, JeKo-1FFluc_eGFP CD19/CD20 ko cells were generated. For this purpose, JeKo-
1FFluc_eGFP CD20 ko cells were again co-transfected with 1 µg Cas9 encoding plasmid and 
1 µg gRNA 19.2. Single cell clones were generated as described above using LD-columns 
and a single cell expansion strategy.  
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2.5  Functionality assays 
Unless mentioned to the contrary, kits were used according to the manufacturer´s protocol. 
2.5.1  Flow-based killing assay 
5E6 target cells were labeled with CellTrace Violet Dye (500 µM) in a 1:500 solution in 
PBS for 5 min at 37°C and 5% CO2 atmosphere. Subsequently, 5 ml FCS and 5 ml 
TexMACS were added and cells were pelleted at 300 g for 10 min. Cells were then 
resuspended in TexMACS, counted using a hemocytometer and adjusted to 1E5 cells/ml. 
That followed, 1E4 VioDye-positive target cells were seeded in 100 µl into 96-well round 
bottom plates before either 100 µl Mock-transduced or 100 µl CAR-positive T cells were 
added in different effector to target ratios and the plates were centrifuged for 1 min at 100 
g. Mock was always adjusted to pipette similar cell numbers. Each sample was measured 
in duplicates. Blank was defined as 100 µl labeled target cells with 100 µl TexMACS. After 
4 - 24 h cultivation at 37°C and 5% CO2 atmosphere plates were incubated for 20 min at 
4°C and then, after adding PI (titer 1:100) to discriminate death cells, 70 µl per well were 
analyzed via flow cytometry (Cap. 2.3.7). PI-negative, VioDye-positive cells were defined 
as viable target cells which allowed to calculate the killing frequency using the following 
equation: 
Killing [%] = (1 −
count sample
count blank
) x 100 
2.5.2  Bioluminescence-based killing assay 
For standard killing assays, 2E5 cells/ml FFluc-expressing target cells (Cap. 2.4.4) were 
resuspended in TexMACS and 100 µl of the cell suspension were seeded in 96-well 
black well plates before 100 µl effector cells from a serial dilution (e.g. 10:1; 5:1; 2.5:1; 
1.25:1) starting with 2E6 Mock transduced or CAR expressing T cells were added. Mock 
was always adjusted to pipette similar cell numbers. All samples were measured in 
duplicates. At least six wells were used as `target alone´ and `target lysed´ sample were 
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no effector cells were added. To the latter, additionally 4 µl/200 µl/well of 50% Tween-20 
in TexMACS was pipetted. Plates were then centrifuged for 1 min at 100 g and cultured 
for 18 h at 37°C and 5% CO2 atmosphere. The next day, 100 µl of a XenoLight D-Luciferin-
K+ Salt solution (300 µg/ml in TexMACS) was added into every well and CPS was 
measured after 5 min of incubation using the VICTOR X4 2030 Multilabel Reader. Specific 
killing was calculated using the following equation: 
Killing [%] = ( 1 − (
CPS sample − CPS target lysed 
CPS target alone − CPS target lysed
)) x 100 
 
Relative frequency of killed target cells represents the delta between Mock and effector 
cell killing. 
For boosting experiments, 1E5 - 4E5 cells/ml FFluc expressing target cells (Cap. 2.4.4) 
were resuspended in TexMACS and 50 µl seeded in 96-well black well plates before 50 
µl CD20-positve cells from a serial dilution (e.g. 10:1; 5:1; 2.5:1; 1.25:1) starting with 4E6 
cells/ml and 100 µl effector cells with the same serial dilution starting with 2E6 cells/ml of 
Mock or CAR engineered T cells were added. Subsequently, cells were cultured and 
analyzed as described above. 
2.5.3  Cytokine release assay 
1E4 – 2E5 target cells were co-cultured with either 5E4 - 1E5 Mock-transduced or CAR-
positive T cells in a total volume of 200 µl in a 96-well pate. For trans-boosting experiments 
5E4 - 1E5 CD20-positive cells were additionally added. Mock was always adjusted to 
pipette similar cell numbers. All samples were measured in duplicates. After pipetting, 
cells were centrifuged for 1 min at 100 g. After 24 h the cytokine secretion was determined 
in the supernatant using the MACSPlex Cytokine 12 Kit, human.  
Material and Methods 
 
39 
 
2.5.4  IncuCyte-based killing assay 
2E4 Mel526FFluc_eGFP or CD20-positive Mel526FFluc_eGFP, resuspended in TexMACS, were 
co-cultured with either CAR-positive effector or untransduced (Mock) T cells at different 
effector to target ratios (e.g. 10:1; 5:1; 2.5:1; 1.25:1) in the presence or absence of CD20-
positive cells in 96-well flat bottom plates for up to five days in a total volume of 200 µl 
TexMACS. Mock was always adjusted to pipette similar cell numbers. Killing was 
measured on the basis of target cell GFP expression every 2 h using the IncuCyte device. 
2.5.5  In vivo experiments 
All experiments were performed in compliance with the “Directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 on the protection of 
animals used for scientific purposes”. 
In vivo performance of anti-CD20 CAR sequence expressing T cells was tested in NOD 
scid gamma (NSG) (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice. For this purpose, 5E5 FFluc-
expressing target cells were injected via tail vain. Tumor cells were engrafted for seven 
days before either 1E6 Mock-transduced or CD20-directed T cells were injected i.v.. 
Tumor growth as well as anti-tumor response was monitored frequently using an In vivo 
Imaging System (IVIS Lumina III). For this purpose, 100 µl XenoLight Rediject D-Luciferin 
Ultra was injected i.p. and subsequently mice were anesthetized using the Isofluran XGI-
8 Anesthesia System. Measurement was performed six min after substrate injection.  
Bone marrow samples were collected from femur and tibia of both legs. After lysing red 
blood cells using 1x Red Blood Cell Lysis Solution, cells were subsequently stained with 
CD45, CD3, CD4, CD8 and CD19 and analyzed by flow cytometry (Cap. 2.3.7). 
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2.6  Statistics 
Statistical significances were calculated with a Student t Test using Graph Pad Prism 7.0. 
Significance was defined as: * = p < 0.05, ** = p < 0.01 and *** = p ≤ 0.001. Unless 
mentioned to the contrary, graphs were all shown as mean with standard deviation.  
2.7  Ethical concerns 
The institutional review board and ethics committee of the university of Cologne approved 
sample collection for this study. Each patient provided written informed consent before 
sample collection in accordance with the declaration of Helsinki. 
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3  Results 
3.1  Technologies and tools 
Novel technologies and tools are of utmost importance to further contribute to the 
remarkable potential of CAR expressing T cells for the treatment of cancer and infectious 
diseases. Thus, during the course of this work, a high-throughput molecular cloning 
strategy as well as a multitude of reporter cell lines and protocols were initially established.  
3.1.1  CAR library generation 
Lentiviral constructs encoding a CAR must ensure expression of a modular structure 
including extracellular binding and spacer domain as well as transmembrane, intracellular 
co-stimulatory and signaling domain. While the specificity of a CAR is directed by its scFv, 
its functionality is also dependent on spatial needs, mediated by the spacer domain [39, 
99] in order to ensure the most productive interaction between CAR T cell and target cell. 
Thus, a library of CAR backbones with variable lengths of extracellular spacers was 
generated. This library was developed to enable the rapid functional testing of different 
scFvs and therefore a robust method to clone scFvs into the library was also developed 
(Fig.  5). The library of backbones comprises either a human IgG4 hinge_CH2_CH3 (long 
spacer; 228 aa), a human IgG4 hinge_CH3 (medium spacer; 119 aa), a human IgG4 hinge 
(extra short spacer; 12 aa) or a human CD8 spacer (short spacer; 45 aa). All IgG4 spacer 
domains contained a 4/2 NQ mutation in the CH2 domain [39] as well as a S→P 
substitution in the hinge region in order to reduce FcR binding [42]. 
The design of these new lentiviral CAR encoding constructs along with the high-
throughput cloning strategy not only simplified the initial cloning procedure but also 
reduced the expenditure of time tremendously. Furthermore, the technique used 
circumvented the need to implement restriction enzyme recognition sites which allowed 
cloning of unmodified wildtype sequences in frame.  
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Fig.  5 Schematic representation of the CAR library. This library comprises the DNA encoding 
elements of a phosphoglycerate kinase (PGK) promoter-driven extracellular binding domain (scFv), linked 
to an extracellular spacer domain with different lengths (long = human IgG4 hinge_CH2_CH3, 228 aa; 
medium = human IgG4 hinge_CH3, 119 aa; short = human CH8 hinge, 45 aa; extra short = human IgG4 
hinge, 12 aa), a human CD8 transmembrane domain, a 4-1BB co-stimulatory and CD3 signaling domain 
as well as a P2A element-linked LNGFR as surface marker. 
For this purpose, the scFv domain of the lentiviral backbone was replaced against a 
selection cassette (Cap. 2.2.2) encoding an inverted, lacZ promoter-driven lacZ gene with 
internally located Bve I sites that enable the high-throughput cloning (Fig.  6A). New scFv 
candidates were synthesized with externally located Bve I sites (Fig.  6B). The Type IIS 
restriction enzyme Bve I cuts outside the non-palindromic recognition sequence and 
generates free selectable 4 nt 5´ overhangs. Thus, allowing to perform digestion and 
ligation within one reaction step, avoiding the need of using pre-digestions with restriction 
endonucleases and gel electrophoresis with subsequent gel extractions and purification 
steps. Accordingly, digestion and re-ligation of the plasmids used occurred until the final 
product was generated as the Bve I recognition sites were separated from the compatible 
sticky end that were ligated and consequently enriched over time. The lacZ gene used 
allowed to visualize the cloning success after transformation (Cap. 2.2.3) on X-Gal 
containing plates by blue/white selection [100, 101]. Additionally implemented BamH I and 
Nhe I flanking sequences (Fig.  6C) enabled further modifications using conventional 
cloning techniques. 
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This cloning system was applicable on the entire CAR library after an initial exchange of 
the primary scFv sequence against the selection cassette with the flanking, internally 
located Bve I sites resulting in the constructs MB_001 – MB_004. 
 
Fig.  6 Cloning of novel scFvs into the CAR library using a lacZ reporter gene. (A) Initially an inverted 
orientated lacZ promoter-driven lacZ gene with internally located Bve I sites (red sequences) was cloned 
into the lentiviral CAR encoding construct. (B) Novel scFv sequences were ordered with externally located 
Bve I sites so that compatible sticky ends are obtained after digestion with the Type IIS restriction enzyme. 
Additionally implemented restriction endonuclease recognition sites (green sequences) allowed further 
modifications of the lentiviral CAR encoding construct when necessary. (C) The new scFv was cloned using 
Bve I and ligase within one reaction. 
This Bve I-based cloning strategy for scFv sequences was further applied to enable the 
rapid exchange of co-stimulatory and signaling domains. For this purpose, the lacZ 
selection cassette with the associated Bve I sites was cloned 3´ of the transmembrane 
encoding region (Cap. 2.2.2), replacing the conventionally used 4-1BB_CD3 sequence 
(Fig.  7A). Novel co-stimulatory or signaling domain encoding sequences were 
synthesized with externally located Bve I sites (Fig.  7B). The free selectable 4 nt 5´ 
overhang was designed in a way that a Pst I, a Sca I and a Pml I recognition site were 
available after ligation in the final construct (Fig.  7C). 
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The generated constructs MB_005 and MB_006 enabled a high-throughput cloning of 
alternative co-stimulatory and signaling domain encoding sequences with different 
spacers either derived from human IgG1 with minor modifications [40] or human CD8. 
 
Fig.  7 Cloning of co-stimulatory and signaling domain encoding sequences. (A) A lacZ encoding 
gene with internally located, flanking Bve I sites was cloned 5´ of the transmembrane sequence enabling a 
highly efficient exchange of sequences. (B) Novel co-stimulatory and signaling domain encoding sequences 
were synthesized with externally located Bve I sites (red sequences). (C) The final lentiviral CAR encoding 
construct could be further modified using the implemented restriction endonuclease recognition sites Pst I, 
Sca I and Pml I (green sequences). 
3.1.2  Generation of transgenic cell lines 
To evaluate the functionality of the generated CAR expressing T cells different target cell 
lines were genetically modified to express a firefly luciferase (FFluc) gene and green 
fluorescent protein (GFP) allowing to perform either bioluminescence-based or flow-based 
in vitro killing assays as well as in vivo imaging. For this purpose, the lentiviral construct 
Doc_1 (Fig.  8) which encodes a phosphoglycerate kinase (PGK) promoter-driven FFluc 
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gene with a P2A-element linked eGFP gene was cloned (Cap. 2.2.2) and subsequently 
viral vector was produced (Cap. 2.3.6).  
 
Fig.  8 Schematic representation of Doc_1. A PGK promoter-driven (PPGK) FFluc gene with a P2A-
element linked eGFP encoding sequence was used to produce lentiviral particles for the transduction of 
several cell lines. (WPRE = woodchuck posttranscriptional regulatory element, a posttranscriptional cis-
acting stabilization element) 
The B cell lines JeKo-1, Raji and NALM6 were transduced with LV-Doc_1 (Cap. 2.4.4). 
After 72 h bulk cells were analyzed using flow cytometry (Cap. 2.3.7) (Fig.  9A). While > 
87% of the transduced JeKo-1 and NALM6 cells were GFP-positive, only 48% Raji cells 
were successfully transduced. To obtain transgenic single cell clones, cells were diluted 
(0.3 cells/well in a 96-well culture plate) and single cell clones were expanded for two 
weeks before GFP gene expression of individual clones was re-analyzed (Fig.  9B). 
Overall, > 99% of the analyzed cells of the different clones were GFP-positive. 
 
Fig.  9 Generation of FFluc expressing B cell lines. JeKo-1, Raji and NALM6 were transduced with a 
lentiviral construct Doc_1 encoding a FFluc and GFP gene. (A) After 72 h GFP gene expression of the bulk 
transduced cells was analyzed via flow cytometry. (B) Subsequently, a single clone expansion was 
performed and after two weeks a uniform GFP expression of individual clones could be detected. 
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Analogue to the generation of the B cell line derived reporter cell lines, the adherent 
CSPG4-positive melanoma cell line Mel526 was initially transduced with LV-Doc_1 (Cap. 
2.4.4). After expanding the single cell clones for two weeks, flow cytometry analysis 
revealed two distinct populations when comparing Mock-transduced and LV-Doc_1-
modified Mel526 clones regarding their GFP expression (Fig. 10).  
  
Fig. 10 Generation of a FFluc expressing melanoma cell line. Mel526 cells were transduced with 
Doc_1. After 72 h a single cell expansion was performed and cells were analyzed again after two weeks 
showing a homogenous GFP expression (red) and two distinct populations compared to the Mock-
transduced control (black). 
Since this work also required a cell line that co-expresses CSPG4 and human CD20 (will 
be clarified further), a single cell-derived Mel526FFluc_eGFP clone was further modified using 
the lentiviral construct with a PGK promoter-driven human CD20 encoding sequence 
(Doc_2). For this purpose, FFluc_GFP-positive Mel526 cells were transduced with LV-
Doc_2 (Cap. 2.4.5). After 72 h CD20-positive cells were enriched using magnetic activated 
cell sorting (MACS) technology. Again a limiting dilution strategy was applied to get CD20-
positive Mel526FFluc_eGFP single cell clones.  
After two weeks of expansion, CD20 expression was analyzed using flow cytometry (Cap. 
2.3.7). While Mel526FFluc_eGFP were completely negative for CD20, the newly generated 
Mel526CD20_FFluc_eGFP uniformly expressed CD20 in a distinct population (Fig. 11). 
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Fig. 11 Generation of a hCD20-positive Mel526FFluc_eGFP clone. A FFluc_GFP-positive Mel526 clone 
was transduced with LV-Doc_2, a PGK promoter-driven human CD20 encoding sequence. Transduced 
cells were enriched using MACS technology and subsequently expanded as single cell clones. After two 
weeks CD20 expression (red) could be confirmed by flow cytometry (black was isotype control). 
In addition, JeKo-1FFluc_eGFP knock-out clones were required as control cell lines for the 
evaluation of CAR modified T cells in vitro as well as in vivo. In the present work CD19, 
CD20 and CD19/CD20 ko JeKo-1FFluc_eGFP were generated using the CRISPR/Cas9 
technology [94] (Cap. 2.4.6). For this purpose, the guideRNA 19.2 and 20.4 were designed 
in silico. Both target the first exon of either CD19 or CD20 and affect all splice variants of 
those genes. Cloning of the guideRNA into the gRNA plasmid as well as co-transfection 
of JeKo-1FFluc_eGFP cells with the Cas9 encoding and gRNA plasmid was mainly done 
within the framework of a Bachelor thesis that I supervised.  
Seven days post transfection, CD19- and CD20-positive cells were depleted using the 
respective microbead reagents and LD depletion columns. Bulk cells were further diluted 
(0.3 cells/well in a 96-well culture plate) and expanded to obtain single cell clones which 
were analyzed after a surface staining with CD19 and CD20 by flow cytometry (Cap. 2.3.7). 
Stained as well as unstained JeKo-1FFluc_eGFP cells were used as control to detect the ko 
of either CD19 or CD20 (Fig. 12A). After two weeks both CD19-negative and CD20-
negative JeKo-1FFluc_eGFP clones could be isolated (Fig. 12B & C). 
CD19/CD20 ko JeKo-1FFluc_eGFP were generated by further modifying JeKo-1FFluc_eGFP 
CD20 ko with guideRNA 19.2/Cas9 targeting the CD19 gene as described above. The 
same limiting dilution strategy was used to obtain single cell clones of CD19/CD20 ko 
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JeKo-1FFluc_eGFP, as confirmed by flow cytometry after staining with CD19-VB and CD20-
APC (Cap. 2.3.7) (Fig. 12D).  
 
 
Fig. 12 Generation of JeKo-1FFluc_eGFP knock-out clones. JeKo-1FFluc_eGFP cells were modified using the 
CRISPR/Cas9 system. Untransfected cells were depleted and ko cells expanded as single cell clones. (A) 
After two weeks, cells were stained with CD19-VB and CD20-APC to analyze the ko by flow cytometry. 
Stained (red) as well as unstained (black) JeKo-1FFluc_eGFP cells were used as control. (B-D) A complete 
stable ko of CD19, CD20 and CD19/CD20 of JeKo-1FFluc_eGFP could be obtained. 
Furthermore, based on similar strategies CT26.wt (colon carcinoma) and B16-F10 
(melanoma), two mouse cell lines, were modified to express FFluc and GFP (Cap. 2.4.4) 
(data not shown) to enable first in vivo experiments using an In vivo Imaging System (IVIS).  
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3.1.3  Testing of FFluc expressing cell lines and IVIS set-up 
As previously reported by Hudecek et al. [39] and confirmed by our own findings (Fig. 25) 
in vivo experiments are of utmost importance for the evaluation of CAR modified T cells. 
Thus, after generating appropriate FFluc expressing cell lines (Cap. 3.1.2), their growth 
potential and the stability of transgene expression had to be tested in vitro as well as in 
vivo by using an IVIS which enables non-invasive monitoring of tumor progression. 
Initially, 4E6 CT26.wtFFluc_eGFP cells (Cap. 2.4.4) were seeded into a 6-well plate. FFluc 
expression and functionality as well as system settings were assessed by adding D-
Luciferin (final concentration 300 µg/ml per well) to three wells (Fig. 13). IVIS 
measurement revealed a specific signal of the bioluminescent reporter only in the 
presence of its substrate which confirmed both functionality and suitability of the used 
FFluc encoding gene to perform IVIS experiments and bioluminescence-based killing 
assays (Cap. 2.5.2). 
 
Fig. 13 In vitro testing of CT26.wtFFluc_eGFP using an IVIS. CT26.wtFFluc_eGFP cells were cultured in a 6-
well plate for 48 h before the FFluc substrate was added. IVIS measurement confirmed a specific signal at 
560 nm only in the presence of D-Luciferin.  
In a next step, representatively 1E6 B16-F10FFluc_eGFP cells were injected s.c. in the flanks 
of BALB/c mice to confirm in vivo the possibility to detect FFluc modified cells. After 18 d 
100 µl XenoLight D-Luciferin - K+ Salt Bioluminescent Substrate (30 mg/ml) was injected 
i.p. and mice were anesthetized using isoflurane prior to the IVIS measurement. Six 
minutes after substrate injection, measurement was initiated revealing an established 
tumor which was further confirmed by an autopsy of the euthanized mice (Fig. 14). 
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Consequently, it could be shown that the FFluc gene, used for the modification of diverse 
cell lines, was allowing to perform both in vitro and in vivo experiments. 
 
Fig. 14 Testing of FFluc expressing cells in vivo using an IVIS. 1E6 B16-F10FFluc_eGFP cells were 
injected s.c. into BALB/c mice. After 18 d the IVIS measurement revealed a tumor engraftment which was 
further confirmed by an autopsy. 
Finally, tumor growth kinetics of JeKo-1FFluc_eGFP cells were assessed. For this purpose, 
5E6 JeKo-1FFluc_eGFP were injected i.v. via the tail vein of NOD scid gamma (NSG) 
(NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice. After four days, 100 µl RediJect D-Luciferin Ultra 
Bioluminescent Substrate (30 mg/ml) was injected i.p.. Subsequently mice were 
anesthetized using isoflurane and bioluminescence was measured. The procedure was 
repeated on day six, 13, 20 und 27 affirming a tumor engraftment in all treated mice as 
well as an exponential tumor growth which correlated with the loss of weight and a 
splenomegaly, determined after euthanizing the mice on day 27 (Fig. 15). A mouse which 
did not receive any tumor cells served as control. Both blood and spleens were further 
analyzed regarding the GFP expression. The isolated spleens were manually dissociated, 
red blood cells of both samples lysed using 1x Red Blood Cell Lysis Solution and 
remaining cells analyzed via flow cytometry (Cap. 2.3.7) to finally verify the functionality 
of both transgenes FFluc and GFP in the used reporter cell line. Consequently, only in 
tumor-bearing mice GFP-positive cells could be detected varying from 72% - 77% in the 
spleen (Fig. 16A) and from 70% - 88% in the blood (Fig. 16B). 
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Fig. 15 Assessing tumor growth kinetics of JeKo-1FFluc_eGFP in NSG mice. 5E6 JeKo-1FFluc_eGFP cells 
were injected i.v. in NSG mice. (A) Tumor growth and weight was measured frequently showing a tumor 
engraftment with an exponential tumor growth (B) and an associated loss of weight. (C) Spleen weight of 
euthanized mice was further analyzed showing an expected splenomegaly. 
 
 
Fig. 16 Analyzing GFP expression of in vivo passaged JeKo-1FFluc_eGFP cells. Blood and spleen of 
euthanized mice was analyzed by flow cytometry. (A) The frequency of GFP-positive cells varied from 72% 
- 77% in the spleen (B) and from 70% - 88% in the blood. No GFP-expressing cells could be detected in the 
untreated control mouse.  
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3.2  Anti-CD20 CAR development and testing 
Although anti-CD19 CAR expressing T cells have demonstrated a remarkable clinical 
success in several clinical trials [26-31], there is still a significant number of patients that 
relapse due to the loss of CD19 gene expression, induced by frameshift and missense 
mutations as well as alternative splicing of CD19 [55-57]. Those relapses are associated 
with a very unfavorable prognosis for the patients [57]. CD20, however, is an antigen 
which is not only highly expressed on more than 90% of B cell lymphomas [44], but also 
on a minor subset of cancer-initiating melanoma cells [60, 61]. Therefore, CD20 is an 
alternative, promising target for adoptive CAR T cell therapy. 
3.2.1 Anti-CD20 CAR development and lentiviral vector 
production 
In the context of this work, several anti-CD20 CAR constructs with minor differences were 
generated and compared. For this purpose, #1455, a gamma-retroviral anti-CD20 CAR 
which was kindly provided by H. Abken (ZMMK Cologne) was modified. For purposes of 
clinical use, it was re-designed in silico, human codon optimized and synthesized at ATUM. 
The 5842 long nt sequence comprises the flanking chimeric Rous sarcoma virus (RSV)-
HIV 5´ long terminal repeat (LTR) [102] and the 3´ LTR with a self-inactivating (SIN) 
modification [103]. Besides, the elongation factor-1 alpha (EF-1 promoter was replaced 
against a human PGK promoter which drives the CAR encoding sequence consisting of 
a murine kappa chain leader sequence, a murine Leu-16-derived scFv (vh/vl orientation, 
linked by a (G4S)3 linker), a human IgG1 spacer with a PELLGGPPVAG and ISRIAR 
mutation [40], a human CD8a transmembrane domain as well as the human intracellular 
co-stimulatory and signaling domains 4-1BB and CD3Fig. 17). In addition, the construct 
comprises a woodchuck posttranscriptional regulatory element (WPRE), a woodchuck 
hepatitis virus-derived cis-acting RNA element, which increases the level of transgene 
expression [104]. The synthesized element was enzymatically digested with Mlu I and Avr 
II and subcloned (Cap. 2.2.2) into the lentiviral backbone pRRL [102]. The resulting 
lentiviral construct CD20_1 was amplified in a maxiprep (Cap. 2.2.4) and sequence 
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verified at GATC. Subsequently, lentiviral particles were produced (Cap. 2.3.6) by co-
transfecting HEK 293-T cells with the helper plasmids pMDG-2 and pCMVdR8.74 in 
combination with the transfer plasmid CD20_1 (Fig. 18).  
 
Fig. 17 Schematic representation of CD20_1. The anti-CD20 CAR encoding construct comprises the 
nucleotide sequences of a PGK promoter (PPGK) driven murine Leu-16-derived scFv, a modified human 
IgG1 spacer, a human CD8a transmembrane domain, a human 4-1BB co-stimulatory domain and a human 
CD3 signaling domain. The cis-acting RNA element WPRE was used to increase the transgene expression. 
The CAR encoding sequence is flanked with modified LTRs. Mlu I and Avr II were used to implement the 
synthesized element into the lentiviral backbone pRRL.  
 
 
Fig. 18 Graphical representation for the generation of lentiviral particles. HEK 293-T cells were co-
transfected with pMDG-2, pCMVdR8.74 and an anti-CD20 CAR encoding construct. After 48 h supernatant 
was harvested, concentrated and either freshly used or stored at -70°C. 
To determine the viral titer of LV-CD20_1, 3E5 Jurkat cells were transduced with either 
1 µl, 0.1 µl or 0.01 µl (done in triplicates) of the thawed lentiviral particles. After 48 h, cells 
were stained with anti-IgG1-Fc-Biotin/anti-Biotin-APC and analyzed via flow cytometry 
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(Cap. 2.3.7) to detect the CAR sequence expression. The frequency of CAR-positive cells 
varied from 84.5 ± 2.32% for 1 µl over 17.1 ± 0.7% for 0.1 µl to 3.9 ± 0.7% for 0.01 µl (Fig. 
19). For the titer calculation, the minimal volume of LV-CD20_1 allowing a clear and 
distinct CAR-positive population to be detected (as low as 0.01 µl) was used. Thus, for 
this lentiviral production batch, a titer of 1.1E9 LV-particles/ml was achieved.  
 
 
Fig. 19 LV-CD20_1 titer determination using Jurkat cells. 3E5 Jurkat cells were transduced with a 
decreasing amount of LV-CD20_1 (n=3). After 48 h the CAR expression was detected via flow cytometry. 
Even with the lowest amount of viral vector a distinct CAR-positive population was detectable. Consequently, 
titer was calculated with a frequency of 3.9 ± 0.7% CAR sequence expressing cells. 
3.2.2 Assessing the cytolytic activity of anti-CD20 CAR modified 
T cells 
The cytolytic potential of lentivirally engineered T cells was initially assessed in vitro and 
in addition compared with retrovirally modified T cells expressing the original #1455 anti-
CD20 CAR. For this purpose, PBMC was prepared (Cap. 2.3.1). Subsequently T cells 
were isolated and activated using a nanomatrix-based polyclonal T cell stimulation 
reagent TransAct (Cap. 2.3.2). Transduction with LV-CD20_1 took place after 48 h with a 
multiplicity of infection (MOI) of four (Cap. 2.4.1). In advance to the retroviral transduction, 
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RV #1455 was generated by co-transfecting HEK 293-T cells with 3 µg pMDG-2, 22.5 µg 
pHit60 and 23.98 µg #1455, analogue to the generation of lentiviral particles (Cap. 2.3.6). 
A spin-based transduction was applied to retrovirally transduce T cells. Accordingly, a 
non-tissue culture treated 48-well plate was coated with 250 µl RetroNectin (10 µg/ml) 
overnight at 4°C. Then, 1 ml PBS/BSA (1%) was added and incubated for 30 min at RT 
before the PBS/BSA blocking solution was removed and 200 µl unconcentrated RV-#1455 
was added and centrifuged with 2000 g for 90 min at 32°C. Subsequently, 0.5 ml T cells 
(1E6 cells/ml) were added and again centrifuged with 540 g for 10 min at 32°C. After 24 h 
incubation at 37°C and 5% CO2 atmosphere T cells were transferred into a 24-well plate 
and cultivated (Cap. 2.3.2). On day eight, CD4/CD8 ratio as well as the CAR expression 
was determined by flow cytometry (Cap. 2.3.7) as exemplarily shown for LV-CD20_1 
transduced T cells (Fig. 20).  
Compared to the Mock control T cells no significant differences regarding the CD4/CD8 
ratio was detectable. The frequency of CD4-positive cells varied from 18 - 53% among 
the three different donors, independently of the transduction. The frequency of CD8-
positive cells, which ranged from 43 - 81%, was higher, however, also no significant 
differences were detectable between Mock, lentivirally or retrovirally transduced T cells. 
The same applied to the CAR-positive population where the lentivirally transduced donors 
expressed the CAR sequence at frequencies from 34 to 50% (mean 44.2 ± 8.8%) and 
retrovirally modified T cells ranged from 31 - 40% (mean 36.2 ± 4.9%) (Fig. 21).  
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Fig. 20 Representative example for the detection of CD4/CD8 ratio and CAR expression of LV-
CD20_1 transduced T cells. T cells were stained with anti-CD4-PE, anti-CD8-VB and anti-IgG Fc-
Biotin/anti-Biotin-APC. CD4/CD8 ratio as well as CAR-positive cells were determined among viable cells 
(PerCP-Vio700 negative). 
 
Fig. 21 Comparison of Mock, lentivirally or retrovirally transduced T cells regarding CD4, CD8 and 
CAR expression. T cells derived from three different donors were either transduced with LV-CD20_1 or 
RV-#1455 and analyzed after 8 days. Significant differences were neither detected for CD4- nor for CD8-
positive cells among Mock or modified T cells. In addition, also for the CAR-positive population, no significant 
differences were detectable among the three donors. Parametric unpaired t-test with 95% confidence level. 
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After confirming the CAR expression of lentivirally and retrovirally transduced T cells, 
functionality assays were performed to assess and compare the cytolytic potential of the 
engineered T cells. For this purpose, autologous B cells were isolated from frozen PBMC 
(Cap. 2.3.3) and used as target cells for a flow-based killing assay (Cap. 2.5.1) in which 
1E4 VioDye-labeled target cells were co-cultured at different effector to target ratios (E:T) 
with either Mock or CAR-positive T cells, both normalized for the CAR expression to use 
identical cell numbers. After 4 h at 37°C and 5% CO2 atmosphere 70 µl resuspended cells 
were analyzed (Cap. 2.3.7). Dead cells were discriminated and the remaining VioDye-
positive B cells as well as a Blank control cultured without effector cells allowed to 
calculate the killing frequency (Fig. 22). Overall, the killing frequencies at E:T 10:1 for 
lentivirally modified T cells varied from 22.8 – 45.4% (mean 36.9 ± 8.6%) and for 
retrovirally engineered T cells from 40 – 57% (mean 47.4 ± 6.4%). Even at the highest 
E:T ratio Mock T cells did not show a noteworthy cytolytic potential. Although the 
retrovirally transduced T cells killed slightly better than lentivirally modified T cells at the 
highest E:T ratio, at the lower 5:1 ratio no significant differences were detectable between 
the both. However, at the lowest E:T ratio of 1:1 the picture changed and the lentivirally 
engineered T cells showed a higher killing potential for donor A and B, not for donor D. 
 
 
Fig. 22 In vitro functionality of lentivirally and retrovirally modified T cells. CAR-positive T cells were 
co-cultured with autologous B cells for 4 h. Subsequently, killing efficiency was measured by flow cytometry. 
While retrovirally modified T cells killed better than lentivirally transduced T cells at the highest E:T ratio, the 
picture changed at a 1:1 E:T ratio where lentivirally engineered T cells of donor A and B were better than 
their counterpart. Mock T cells did not show any cytolytic potential. #A, #B and #D represent different donors. 
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In addition to the killing experiments, cytokine release assays were performed (Cap. 2.5.3). 
Again, 2E5 autologous B cells were co-cultured with 1E5 either Mock or CAR-positive T 
cells for 24 h. The cytokine secretion was subsequently determined using a flow-based 
detection method which confirmed the functional potential of both lentivirally and 
retrovirally transduced T cells (Fig. 23A). Retrovirally modified T cells, however, released 
significantly more type-1 cytokines than the lentivirally engineered T cells (Fig. 23B).  
 
 
Fig. 23 Cytokine release of lentivirally and retrovirally engineered T cells. (A) The supernatant of co-
cultured T cells was used to determine the cytokine release of either lentivirally or retrovirally transduced 
T cells showing that both are inducing the release of type-1 cytokines upon encountering their target while 
Mock T cells did not release IFN-, IL-2 or TNF- in the presence of CD20-positive B cells. (B) Comparing 
the detected cytokine amounts among lentivirally and retrovirally modified T cells revealed a significant 
difference. Parametric unpaired t-test with 95% confidence level. #A, #B and #D represent different donors. 
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3.2.3  Further anti-CD20 CAR modifications and testing 
Note: In the present study, the anti-CD20 CAR encoding lentiviral construct CD20_1 was cloned, lentiviral 
particles produced and T cells transduced. The cytolytic potential of those engineered T cells was confirmed 
using established in vitro assays. Furthermore, this work led to the development and establishment of 
protocols used to assess the potential of CAR modified T cells in vivo. Further modifications of CD20_1 over 
a period of 12 month as well as testing was mainly done by colleagues at Miltenyi Biotec using the said 
established protocols. This chapter briefly summarizes additional modifications of CD20_1 leading to the 
final CAR construct CD20_5 which is intended to be used in two different clinical trials.  
In a proof-of-concept clinical trial (ClinicalTrials.gov Identifier NCT00012207) Till et al. [44] 
confirmed the safety and potential of Leu16-scFv directed engineered T cells for patients 
with relapsed or refractory indolent B cell lymphoma or mantle cell lymphoma. They used 
a first generation CAR with a CD4 transmembrane region and implemented the Leu-16 
scFv, compared to CD20_1, in a vl/vh orientation. To stay as comparable as possible to 
this clinically approved construct, the CD20_1 construct was further refined. Thus, not 
only the scFv orientation was modified according to Till et al. [44] but also originally 
transferred cloning sites were deleted, the murine kappa chain leader sequence was 
replaced against human CD8 leader sequence and the lentiviral backbone was 
exchanged against a CG1711-derived backbone, a self-inactivating lentiviral vector 
packaged by a 3rd generation plasmid (designed and produced under GMP guidelines by 
Cell Genesis Inc.). The resulting constructs CD20_2 and CD20_3 were further 
characterized in Tab. 7. 
Tab. 7 Overview about the differences in the anti-CD20 CAR constructs 
 
CD20_1 CD20_2 CD20_3 
lentiviral backbone pRRL pRRL CG1711 
Generation transfer 
plasmid 
3rd 3rd 3rd 
promoter PGK PGK EF-1 
leader peptide 
murine kappa 
chain 
human CD8 
leader 
human CD8 
leader 
Leu16 scFv orientation vh/vl vl/vh vl/vh 
spacer 
modified 
human IgG1 
modified 
human IgG1 
modified 
human IgG1 
 
Finally, lentiviral particles for all constructs were produced (Cap. 2.3.6), T cells transduced 
(Cap. 2.4.1) and expanded (Cap. 2.3.2) before in vitro experiments (Cap. 2.5.1) were 
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performed allowing to assess the cytolytic potential of the newly generated constructs. 
The JeKo-1 co-culture assays revealed that the three differently modified T cells were all 
functional (Fig. 24). Thus, the frequency of killed JeKo-1 cells among the three donors at 
E:T 1:1 varied for LV-CD20_1 modified T cells from 21.1 – 52.6% (mean 33.7 ± 16.6%), 
for LV-CD20_2 engineered T cells from 34.2 – 56.4% (mean 43.8 ± 11.4%) and for LV-
CD20_3 transduced T cells from 36.0 – 74.9% (mean 56.7 ± 19.5%).  
 
 
Fig. 24 Comparison of differently transduced T cells in vitro. JeKo-1 cells were co-cultured with 
engineered T cells at an 1:1 E:T ratio. The cytolytic potential was measured by flow cytometry after 24 h. 
(unpublished data by Miltenyi Biotec) 
Even though all constructs and especially CD20_3 efficiently killed CD20-positive target 
cells, the two additional constructs CD20_4 and CD20_5 were generated. Both encode a 
human CD8 spacer instead of the modified human IgG1 motif. Furthermore, CD20_5 
contained the Leu-16 scFv in its original vh/vl orientation. After confirming their 
functionality in vitro (data not shown), the anti-tumor reactivity of LV-CD20_3 and LV-
CD20_5 transduced T cells was tested in a xenograft model (Cap. 2.5.5) showing that 
only the latter was able to control the tumor outgrowth in the NSG mice (Fig. 25). The in 
vivo comparison of LV-CD20_4 and LV-CD20_5 engineered T cells furthermore revealed 
that the Leu-16-derived vh/vl scFv orientation has a higher cytolytic potential than the 
counterpart with the opposite vl/vh orientation (data not shown).  
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Fig. 25 Comparison of LV-CD20_3 and LV-CD20_5 transduced T cells in vivo. After establishing a 
tumor with RajiFFluc cells in the NSG mice CAR engineered T cells were injected i.v. and tumor growth was 
monitored frequently for 21 days using an IVIS. Only LV-CD20_5 engineered T cells with a CD8 spacer 
instead of the IgG1 spacer were able to control the tumor outgrowth. (n=7) (unpublished data by Miltenyi 
Biotec) 
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3.3  Automated manufacturing of CAR T cells 
Note: All data, tables and figures presented in this chapter were published by Lock et al. as a collective work 
which is subdivided as follows: Drechsel K. TCT software development; Barth C., Mauer D. and Kolbe C. 
technical support including flow cytometric analysis and TCT operation; Al Rawashdeh W. and Brauner J. 
in vivo experiment; Lock. D and Schaser T. lentiviral vector development; Lock D. establishment of protocols, 
cell lines and tools enabling to perform in vitro as well as in vivo experiments; Lock D. and Mockel-Tenbrinck 
N. data analysis and leading authors; Assenmacher M., Mockel-Tenbrinck N. and Kaiser A. project 
managers. 
The success of CAR T cell therapies for the treatment of B cell leukemia and lymphomas 
has been confirmed in several clinical trials [26-31], however, the manufacturing process 
of such engineered T cells is complex requiring extensively trained operators and a special 
working environment [66, 70]. Thus, the dissemination of CAR T cells therapies to a wider 
field of patients is strongly dependent on an improved and simplified cGMP-compliant 
manufacturing process for engineered T cells. 
3.3.1 Robustness of the automated T Cell Transduction Process 
Taking advantage of the CliniMACS Prodigy platform, a fully-closed, automated T Cell 
Transduction (TCT) Process was used to manufacture gene-engineered T cells in a 
closed tubing set (Cap. 2.4.2) (Fig. 26). Initially, CD4- and CD8-positive T cells were 
magnetically isolated from either healthy donor (HD)- or patient material (PM)-derived 
leukapheresis (LP), whole blood (WB) or buffy coat (BC), activated and after 24 h 
transduced with aseptically conjoined anti-CD20 CAR encoding lentiviral particles. 
Subsequently, T cells were expanded for additional eleven days and finally harvested on 
day twelve. 
To assess reproducibility and robustness of the TCT Process, 15 runs with different 
conditions were performed. Thus, the process was challenged by the use of either HD or 
PM as starting material, by their status which was fresh and frozen or only limited available. 
Tab. 8 summarizes the characteristics of the donors used for the different runs.  
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Fig. 26 The automated TCT Process on the CliniMACS Prodigy platform. CD4- and CD8-positive T 
cells, derived from either LP, WB or BC, were magnetically isolated, activated and after 24 h lentivirally 
transduced. Subsequently, genetically engineered T cells were expanded for additional eleven days and 
finally formulated in Composol and harvested. QC pouches enabled a consequent in-process control to 
check cell count, viability, pH value and glucose consumption. 
 
 
Tab. 8 Characterization of starting material used to evaluate robustness and reproducibility of the TCT 
Process. 
 
Run ID 
starting 
material 
donor 
description 
cryopre-
served 
transduction 
performed 
% CD3-positive 
starting 
material 
number TNC 
start culture 
with 
LP-1 LP HD no yes 81 1E8 
BC-2 BC HD no yes 59 1E8 
WB-3 WB melanoma no yes 4 0.2E8 
LP-4 
LP *) DLBCL no 
yes 
19 
1E8 
LP-5 no 1E8 
LP-6 
LP *) HD no 
no 
63 
1E8 
LP-7 yes 1E8 
LP-8 yes 1E8 
LP-9 
LP *) DLBCL yes 
yes 
46 
0.6E8 
LP-10 yes 0.6E8 
LP-11 
LP *) HD no 
yes 
83 
1E8 
LP-12 yes 1E8 
LP-13 
LP *) HD no 
yes 
75 
1E8 
LP-14 yes 1E8 
LP-15 yes 1E8 
 
*) split pack run: enriched T cell fraction was used for manufacturing runs on different CliniMACS Prodigy 
devices 
Generally, 1E8 CD4/CD8 enriched T cells (less for run WB-3, LP-9 and LP-10; Tab. 8) 
were polyclonally activated. After 24 h as well as 72 h their activation status was 
qualitatively assessed without disturbing the initial T cell activation phase or losing cells 
in the early beginning by using an integrated microscope camera (Fig. 27A). Considering 
the fact that WB-3 started with just 2E7 cells instead of 1E8, all 15 Prodigy runs yielded 
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comparable T cell expansion curves (Fig. 27B) that ranged from 2.9E9 – 6.3E9 T cells for 
HD to 3.2E9 – 4.9E9 lymphocytes for DLBCL patients and 2.4E9 cells for the melanoma 
patient on day twelve (Fig. 27C). Neither for the final cell count nor for the final cell density 
(17.2E6 ± 5.5E6 cells/mL for HD and 14.0E6 ± 3.7E6 cells/mL for PM; Fig. 27D) were 
significant differences observed even though cryopreserved material (LP-9 and LP-10) or 
lower starting numbers (WB-3, LP-9 and LP-10) were used to run the process. 97.8% of 
fresh cells (LP-4 and LP-5) were initially viable compared to 82.4% starting with the 
cryopreserved product (LP-9 and LP-10) (Fig. 27E). However, while this value dropped 
for the fresh cells to 81.3 ± 2.5% and increased back to 91.8 ± 0.7%, the viability of 
cryopreserved cells peaked at 93.1 ± 4.2% on day six and then continuously decreased 
to 80.7 ± 2.4% on day twelve. Overall, no statistically significant differences were 
detectable when analyzing the viability in the final product which ranged from 90.4 ± 4.3% 
for HD and 88.4 ± 7.4% for PM (Fig. 27F). The final expansion rates varied from 43 ± 14 
fold for HD and from 65 ± 36 fold for PM (Fig. 27G). 
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Fig. 27 The TCT Process allows the manufacturing of T cells in a clinically relevant scale 
independently of the starting material. (A) The activation status of polyclonally activated T cells was 
qualitatively assessed after 24 h and 72 h using the CliniMACS Prodigy integrated camera. (B) 
Independently of the starting material, comparable T cell expansion curves, (C) final cell counts as well as 
(D) final cell densities were measured. (E) Generally, the viability was > 80% during the process and ranged 
from (F) 90.4 ± 4.3% for HD and 88.4 ± 7.4% for PM in the final product. (G) Overall, the final expansion 
rates were comparable for HD and PM. (* = cryopreserved cells) Parametric unpaired t-test with 95% 
confidence level. 
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3.3.2 Phenotypic characteristics of automated manufactured T 
cells 
Analyzing the cellular composition of the enriched fraction (Cap. 2.3.7) revealed that HD-
derived samples with 83.4 ± 9.6% were mainly composed of CD3-positive cells in contrast 
to PM-derived samples (54.8 ± 11.5% T cells) where significantly more B cells (CD19+), 
monocytes (CD14+), NK cells (CD56+), NKT cells (CD3+/CD56+) and granulocytes 
(CD16±/CD56±/SSChi) were detected (Fig. 28A). In the final product, however, the 
frequency of T cells with 91.3 ± 5.0% for HD and 88.3 ± 7.1% for PM was comparable 
(Fig. 28B). Hence, the established culture conditions favored a T cell outgrowth and only 
NKT cells were further detectable as `contaminating´ cells with frequencies of 5.1 ± 2.2% 
for HD and 8.0 ± 4.3% for PM. Analogue to the cellular composition, phenotypical 
characteristics were analyzed by flow cytometry (Cap. 2.3.7) using CD62L, CD45RO and 
CD95. It was shown that the enriched HD fraction was equally composed of naïve T cells 
(TN: CD45RO-CD62L+CD95-; 26.1 ± 16.5%), central memory T cells (TCM: 
CD45RO+CD62L+CD95+; 22.0 ± 13.0%) and effector memory T cells (TEM: 
CD45RO+CD62L-CD95+; 28.5 ± 10.6%) while the enriched PM fraction contained 
significantly more effector T cells (TEFF: CD45RO-CD62L-CD95+; 24.7 ± 11.3%) whereas 
TN with 7.3 ± 0.5% were significantly diminished (Fig. 28C). Although the PM-derived 
T cells contained more differentiated effector cells in the enriched fraction, 64.7 ± 5.8% 
T cells in the final product showed the phenotypical characteristics of long-term persisting 
TCM. HD-derived T cells were mainly composed of stem cell memory T cells (TSCM: 
CD45RO-CD62L+CD95+; 45.0 ± 11.2%) and TCM (33.99 ± 15.31%) (Fig. 28D). Overall, 
the frequency of memory T cells in the final product was comparable for HD (79.0 ± 13.5%) 
and PM (87.1 ± 7.7%). Finally, the frequency of CD4- and CD8-positive T cells in the 
enriched fraction (Fig. 28E) was analyzed (Cap. 2.3.7) revealing a CD4/CD8 ratio of 3.8 
± 0.8 for HD and 2.3 ± 0.8 for PM (Fig. 28F) that changed during the twelve day culture in 
the final product to 2.0 ± 1.6 for HD and 1.9 ± 0.9 for PM (Fig. 28G and H). 
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Fig. 28 Cellular composition, phenotypical characteristics and CD4/CD8 ratio of the final TCT 
Process product are comparable for HD and PM. Frequencies of T: T cells, B: B cells, M: monocytes, 
NK: NK cells, NKT: NK T cells and G: granulocytes (total of eosinophils and basophils) were analyzed (A) 
before and (B) after the finished TCT Process confirming that the culture conditions favor a T cell outgrowth. 
T cell phenotype was measured using CD45RO, CD62L and CD95 to define TN: naïve T cells, TSCM: stem 
cell memory T cells, TCM: central memory T cells, TEM: effector memory T cells and TEFF: effector T cells. (C) 
While HD-derived T cells showed less differentiated phenotypical characteristics than PM-derived samples 
(D) the frequency of long-term persisting memory T cells was comparable. (E-F) The same applies to the 
frequency and ratio of CD4/CD8 T cells in the enriched fraction (G-H) where significant differences 
disappeared in the final product. (For the enriched fraction in total n=5 runs with HD and n=3 runs with PM. 
For the final product in total n=10 runs with HD and n=5 runs with PM.) Parametric unpaired t-test with 95% 
confidence level. 
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3.3.3 Anti-tumor reactivity of automated manufactured CAR T 
cells 
Transduction efficiency of lentivirally engineered T cells was measured using a CD20 
peptide linked to PE (Cap. 2.3.7). The frequency of CAR expressing T cells ranged for HD 
samples from 14.0 – 28.0% (mean 25.2 ± 7.8%) on day five to 17.3 – 54.3% (mean 34.5 
± 11.7%) one week later (Fig. 29A). PM-derived samples showed a similar expression 
profile with 21.4 – 24.0% (mean 22.2 ± 1.2%) for PM in the in-process control on day five 
and 22.2 – 59.1% (mean 36.4 ± 17.7%) on day twelve (Fig. 29B). Accordingly, not only 
the final T cell count (HD 4.4 ± 1.4E9 and PM 3.6 ± 1.1E9) but also similar transduction 
efficiencies as well as the final number of CD20-directed CAR T cells (HD 1.4 ± 0.7E9 and 
PM 1.0 ± 0.4E9) confirmed both robustness and reproducibility of the automated 
manufacturing process showing that neither starting material nor cryopreservation seems 
to negatively influence the final product (Tab. 9). 
Tab. 9 Characterization of automatically manufactured T cells  
Run ID 
final T cell 
count  
(x1E9 cells) 
% anti-CD20 CAR T 
cells 
final number anti-CD20 
CAR T cells  
(x1E9 cells) 
lentiviral 
vector 
batch 
Operator 
Healthy donor 
LP-1 3,01 42.41 1,28 A A 
BC-2 2,64 40.53 1,07 A A 
LP-7 3,08 35.95 1,11 A B 
LP-8 2,61 40.56 1,06 B C 
LP-11 3,42 22.20 0,76 B B 
LP-12 4,21 17.36 0,73 D D 
LP-13 5,80 24.00 1,39 G D 
LP-14 5,61 32.88 1,85 E B 
LP-15 5,61 54.33 3,05 F D 
  4.42 (±1.40) 34.47 (±11.67) 1.36 (±0.71)     
Patient material 
WB-3 2,11 59.10 1,25 A A 
LP-4 3,33 41.90 1,40 A D 
LP-9 4,17 22.21 0,93 C B 
LP-10 2,56 22.53 0,58 D C 
  3.55 (±1.05) 36.44 (±17.69) 1.04 (±0.36)     
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After the twelve days of manufacturing, CD20-directed T cells, either derived from HD or 
PM, were subsequently used in in vitro assays to assess their cytolytic potential (Fig. 29C 
and D). The frequency of killed target cells varied at an E:T ratio of 1:1 from 13.9 - 75.0% 
(mean 44.2 ± 19.3%) for HD and from 15.4 - 70.7% (mean 39.3 ± 21.3%) for PM (Cap. 
2.5.1). Thus, independently of the starting material or starting conditions, potent CAR 
engineered T cells were manufactured during the TCT Process which was further 
confirmed in cytokine release assays (Cap. 2.5.3) (Fig. 29E and F). 
 
 
Fig. 29 Potency of automatically manufactured CAR T cells was confirmed in vitro. CAR expression 
of (A) HD- and (B) PM-derived T cells was measured during the process on day five as well as in the final 
product on day twelve. Subsequently, co-culture assays with JeKo-1 cells were performed showing a 
comparable killing efficiency for (C) HD- (n=7) and (D) PM-derived samples (n=4) (Each sample tested in 
duplicates, SEM indicated) (E-F) as well as a comparable release of cytokines (HD n=3; PM n=2). 
After verifying the cytolytic potential of automatically manufactured T cells in vitro, their 
anti-tumor reactivity was assessed in vivo using a lymphoma xenograft model (Cap. 2.5.5). 
Hence, 5E5 RajiFFluc cells were injected i.v. into the tail vein of NSG mice. Tumor cells 
were engrafted for one week before either 1E6 Mock-transduced or anti-CD20 CAR 
T cells (HD-derived) were injected again i.v. via their tail vein. Tumor growth was 
monitored frequently for 20 days using an IVIS (Fig. 30A). It could be shown that only mice 
Results 
 
70 
 
that received anti-CD20 CAR sequence expressing T cells were able to eradicate tumor 
cells and thus control tumor outgrowth (Fig. 30B and C). Those findings were further 
confirmed post mortem by analyzing the frequency of tumor cells in the bone marrow 
using flow cytometry (Cap. 2.3.7) (Fig. 30D). 
 
 
 
Fig. 30 Automatically manufactured CD20-directed T cells eradicated tumor cells in vivo. (A) After 
engrafting a RajiFFluc* tumor in NSG mice, either Mock or CD20-directed CAR T cells were injected i.v. as 
described in the experimental workflow. (B-C) While the treatment with Mock T cells did not have any effect 
on the tumor outgrowth, anti-CD20 CAR T cells efficiently lysed tumor cells as detected by IVIS as well as 
(D) flow cytometry. (* = flux on day 0)  
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3.4 Chimeric co-stimulatory receptor as a novel CAR T 
cell technology 
The treatment of solid tumors with CAR engineered T cells is still more than challenging. 
Thus, a fundamental problem still represents the scarcity of known specific tumor-
associated antigens allowing a defined and safe therapy without causing severe on-
target/off-tumor toxicities. In addition, the clinical success of current approaches is limited 
due to the poor infiltration of gene-engineered lymphocytes into the tumor as well as a 
highly immunosuppressive tumor microenvironment which heavily impedes the instigation 
and maintenance of any inevitable T cell response [105]. Novel CAR T cell technologies, 
however, might have the potential to circumvent those limitations and therefore extend 
the scope of ACT.  
Additionally to the development of an anti-CD20 CAR and the automated manufacturing 
of gene-modified T cells, this study also focused on a strategy to ameliorate the CAR-
based immune response in a solid tumor setting by co-expressing a second generation 
CAR and a CCR in the same T cell. 
3.4.1  Anti-CSPG4 CAR and anti-CD20 CCR development  
The present study takes place in a melanoma setting to evaluate the potential of a CCR 
as a tool to enhance the cytolytic potential of CAR T cells. For this purpose, a CAR directed 
against chondroitin sulfate proteoglycan 4 (CSPG4) as well as a CCR specific for CD20 
were generated and tested. 
CSPG4_1, a retroviral construct encoding an anti_CSPG4 CAR, was a kind gift from H. 
Abken (ZMMK Cologne) which was enzymatically digested with BamH I and Sal I and 
subsequently cloned into MB_001 (Cap. 2.2.2). Furthermore, the scFv sequences derived 
from either TP 61.5, 225.28s or 763.74 were cloned into the CAR library using Bve I (Cap. 
2.2.2 and Cap. 3.1.1) (Fig. 31). After sequence amplification in a midiprep (Cap. 2.2.4) 
and sequence verification (Cap. 2.2.5), lentiviral particles were produced (Cap. 2.3.6) and 
subsequently T cells transduced (Cap. 2.4.1) to assess the functionality (Cap. 2.5.2 and 
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2.5.3) of the different lentiviral constructs dependent on the used binding domain and 
spacer length (data not shown). 
 
Fig. 31 Schematic description of Bve I generated anti-CSPG4 CAR encoding lentiviral constructs.  
225.28s-, TP 61.5- and 763.74-derived scFv sequences were cloned into the established and described 
CAR library.  
After confirming the functionality of CSPG4_2, a lentiviral construct encoding for the 
225.28s-derived binding moiety with a long spacer (IgG4 Hinge_CH2_CH3), different 
CCR encoding constructs were generated. Therefore, different signaling motif encoding 
sequences were synthesized with flanking Bve I sites and cloned into MB_005 (Leu16 
scFv vl/vh with long IgG1 spacer) using the established high-throughput cloning protocol 
(Cap. 2.2.2 and Cap. 3.1.1). For a first screening experiment, five lentiviral constructs with 
different combinations of 4-1BB, CD28 and CD3 as signaling domains were generated 
(Fig. 32). Again, midipreps were performed (Cap. 2.2.4), sequence was verified (Cap. 
2.2.5) and lentiviral particles were produced (Cap. 2.3.6).  
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Fig. 32 Overview of anti-CD20 CCR encoding lentiviral constructs. Different combinations of 4-1BB, 
CD28 and CD3 were cloned into MB_005 using the established high-throughput cloning protocol. 
3.4.2  In vitro evaluation of the boosting concept 
To test the boosting CCR concept, PBMC of two different donors were prepared (Cap. 
2.3.1), T cells were isolated and activated (Cap. 2.3.2) and subsequently co-transduced 
with LV-CSPG4_2 and one CCR encoding lentiviral particle (CD20_6 – CD20_10). 
Controls were only transduced with one CAR or CCR encoding lentiviral construct, 
respectively. T cells were then expanded in TexMACS supplemented with 200 IU IL-2 
(Cap. 2.3.2) until gene-modified T cells were enriched (Cap. 2.4.3) on day seven. The 
magnetically selected T cells were further expanded, initially without any re-stimulation, 
for additional six days (Fig. 33A). On day 13, after confirming the CSPG4 gene expression 
of Mel526 cells (Fig. 33B), 1E4 melanoma cells were co-cultured with 5E4 either Mock, 
controls (expressing either CAR or CCR) or T cells expressing both CAR and CCR in the 
presence or absence of 5E4 CD20-positive autologous B cells which were isolated from 
frozen PBMC, one day in advance (Cap. 2.3.3). The applied trans-boosting experiment 
was used to assess the different CCR constructs (Fig. 33C) by analyzing the release of 
cytokines (Cap. 2.5.3). Alternatively, CCR and CAR co-expressing T cells can be 
compared in a cis setting using target cells that express both genes CSPG4 and CD20 
(Fig. 33D). 
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Fig. 33 Schematic workflow of a trans-boosting approach to assess and compare the potential of 
different CCRs. (A) Within 19 days the boosting CCR potential could be tested using co-culture assays. 
(B) CSPG4 gene expression on Mel526 cells (red) was detected via a specific surface staining and flow 
cytometry. (C) Graphical representation of a trans-boosting approach. In this setting, a non-tumor-
associated target gene was used to activate the CCR on the T cells. (D) Alternatively, CAR and CCR 
sequence co-expressing T cells were tested in cis. Accordingly, both CAR and CCR get activated via tumor-
associated surface proteins. 
An enhanced release of TNF- was detected for the CCRs with either 4-1BB_4-1BB or 
CD28_4-1BB endodomains while for the other CCR versions no TNF- was detectable 
(Fig. 34A). The boosting potential of 4-1BB_4_1BB and CD28_4-1BB equipped CCRs 
was further confirmed by measuring additional proinflammatory cytokines including GM-
CSF, IFN- and IL-2 (Fig. 34B). Mock as well as anti-CSPG4 CAR T cells served as control, 
revealing an expected result. Thus, unmodified Mock T cells did not release any cytokines 
while CSPG4-directed T cells released only low quantities of the analyzed cytokines.  
Those findings were further confirmed in a second experiment. Therefore, double 
transduced T cells were generated again as described above aside from the culture 
medium which was supplemented with 12.5 ng/ml IL-7 and IL-15, respectively. 
Furthermore, after the LNGFR/EGFR co-enrichment (Cap. 2.4.3) cells were re-stimulated 
with T Cell TransAct, human (1:500) for two days. Functionality assays were performed 
on day 16 in trans using autologous B cells as well as in cis using CD20-positive 
Mel526FFluc_eGFP cells (Cap. 2.5.3). This experiment focused on a further comparison of 4-
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1BB_4-1BB and CD28_4-1BB and included additional controls. CCR controls (T cells that 
just express the CCR sequence) were analyzed as well. In the trans experiment, a 
boosted release was detected for all the analyzed proinflammatory cytokines (GM-CSF, 
IFN-, IL-6 and TNF- only in the presence of both targets CSPG4 and CD20 (Fig. 35A). 
4-1BB_4-1BB modified CCRs, however, have a greater potential to increase the release 
of this cytokines compared to CD28_4-1BB equipped ones. Donor variances were 
detected with regard to this boosting effect. Nevertheless, CSPG4 as well as CCR controls 
showed a unique cytokine expression profile, independently of added B cells. Mock T cells 
co-cultured with Mel526 cells and B cells as well as Mel526 cells on their own did not 
release any cytokines. The results of the cis experiment were comparable (Fig. 35B). 
Hence, only T cells that express both transgenes CAR and CCR showed an increased 
release of cytokines compared to CAR and CCR controls. Again, Mock T cells as well as 
the target cell line Mel526CD20_FFluc_eGFP did not release any cytokines. Interestingly, the 
unleashed amounts of GM-CSF, IFN- and TNF- either in cis or in trans were virtually 
similar (Fig. 35C). Only for IL-6 appreciable differences were observed. 
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Fig. 34 CCRs equipped with defined endodomains have the potential to enhance a CAR T cell 
response. CAR and CCR co-expressing T cells were co-cultured with CSPG4-positive Mel526 cells in the 
presence or absence of CD20-positive B cells. (A) Initially, the release of TNF- was measured showing 
that CCRs with the combinations of 4-1BB_4-1BB as well as CD28_4-1BB endodomains led to an increased 
release of this cytokine. (B) This finding was confirmed by analyzing additional cytokines. Thus, only in the 
presence of B cells a boosted immune response was detected. CSPG4-directed CAR T cells as well as 
Mock T cells served as control. #A and #B represent different donors. The indication CSPG4 means that 
the T cells in this group were CAR transduced. The indication after the `&´ (e.g. 4-1BB_4-1BB) stands for 
the endodomains of the CCR directed against CD20.  
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Fig. 35 CCRs with 4-1BB_4-1BB endodomains have higher boosting potential than CCRs with 
CD28_4-1BB. (A) Only in the presence of both surface antigens CSPG4 and CD20 an increased release of 
the type-1 cytokines GM-CSF, IFN-, IL-6 and TNF- were detected whereby the released amounts were 
considerably higher for 4-1BB_4-1BB equipped CCRs than for those with CD28_4-1BB endodomains. (B) 
Those findings were further confirmed in a cis experiment where CD20-positive Mel526 clones were co-
cultured with the transgenic T cells. Overall, Mock T cells co-cultured with Mel526 clones in cis or with 
B cells in trans did not release any cytokines. The same applies to the used Mel526 clones cultured without 
effector cells. (C) Except for IL-6, the released cytokine amounts were almost similar among the performed 
cis and trans experiment. #A and #B represent different donors. The indication CSPG4 means that the 
T cells in this group were CAR transduced. The indication after the `&´ (e.g. 4-1BB_4-1BB) stands for the 
endodomains of the CCR directed against CD20. 
3.4.3  Generation and assessment of additional CCRs 
To further investigate the relevance of 4-1BB and CD28, the two endodomains in the CCR 
that demonstrably enhanced the CAR immune response, the current CCR library was 
supplemented by additional combinations including 4-1BB alone, CD28_CD28 and CD28 
alone (Fig. 36). The lentiviral constructs were generated using Bve I (Cap. 2.2.2 and Cap. 
3.1.1) and used for the production of lentiviral particles (Cap. 2.3.6). In vitro functionality 
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experiments with two donors were initiated as already described (Cap. 3.4.2). T cells were 
cultured in TexMACS supplemented with 12.5 ng/ml IL-7 and IL-15. 
 
Fig. 36 Novel CCR encoding lentiviral constructs used to assess the importance of 4-1BB, CD28 
as well as a combination thereof in the boosting context. Additional combinations of 4-1BB- and CD28-
derived endodomains were cloned into MB_005 (Leu16 scFv vl/vh with long IgG1 spacer) and further 
investigated in functionality assays after transducing T cells. 
Transgenic LNGFR and EGFR expression was measured by flow cytometry (Cap. 
2.3.7) on day six exemplified for one donor (Fig. 37A). Overall, the frequency of co-
transduced T cells that co-expressed both transgenes varied from 9 – 19%. The next day, 
gene-modified cells were magnetically enriched (Cap. 2.4.3) and two days later re-
analyzed via flow cytometry as exemplified for the same donor (Fig. 37B). The frequency 
of T cells that co-expressed LNGFR as well as EGFR raised to a range of 31 – 69%.  
On day 16, functionality assays were performed including a cytokine release assay (Cap. 
2.5.3) as well as bioluminescence based killing assays (Cap. 2.5.2). In those experiments, 
due to a limited availability of B cells for some donors, CD20-positive JeKo-1 cells were 
used to activate the CCR in trans. Thus, for the trans cytokine detection assay 2E4 Mel526 
cells were co-cultured with 1E5 effector cells including Mock, controls and T cells 
expressing both sequences CAR and CCR in the presence or absence of 1E5 JeKo-1 
cells. After 24 h the cytokine secretion was determined in the supernatant. At first, TNF- 
release of differently co-transduced T cells was compared revealing that all of them have 
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the potential to boost the cytokine release varying from 37 – 380 fold, however, only when 
the CAR and CCR was activated simultaneously (Fig. 38). T cells that only express the 
transgenic CCR, even though co-cultured on Mel526 in the presence of JeKo-1, did not 
release noticeable amounts of TNF-. 
 
 
Fig. 37 Frequency of CAR and CCR co-expressing T cells could be enhanced using a double-
enrichment strategy. Transgenic LNGFR and EGFR co-expression was analyzed by flow cytometry 
using anti-LNGFR-APC and anti-EGFR-PE antibodies (A) pre- and (B) post enrichment.  
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Fig. 38 Only simultaneous activation of CAR and CCR resulted in a boosted TNF- release. 
Engineered T cells were co-cultured on Mel526 cells in the presence or absence of JeKo-1 cells revealing 
a boosting potential for all tested CCRs. #A and #B represent different donors. 
 
Analyzing the release of additional proinflammatory cytokines like IFN-, IL-2 and IL-6 
further proved the boosting potential of 4-1BB and CD28 endodomains equipped CCRs 
(Fig. 39). As a result, it was not possible to define any decisive advantage for a given CCR 
endodomain in the used in vitro trans-experiment since the cytokine release pattern was 
approximately identical. Minor differences most likely resulted from varying transduction 
efficiencies of the engineered T cells. 
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Fig. 39 CCRs equipped with 4-1BB and/or CD28 endodomains equally boost the cytokine release 
in vitro. (A) 4-1BB_4-1BB, (B) 4-1BB, (C) CD28_4-1BB, (D) CD28 or (E) CD28_CD28 endowed CCRs 
induced the release of comparable amounts of cytokines. Hence, it was not possible to define a most 
favorable construct in this experiment. #A and #B represent different donors. (50000 pg/ml was the detection 
limit) 
The cytokine release experiment in cis was performed analogue to the trans experiment 
(Cap. 2.5.3). 2E4 MelCD20_FFluc_eGFP cells were co-cultured with 1E5 either Mock, controls 
or transgenic CAR T cells expressing CAR and CCR for 24 h. Measuring the expressed 
cytokine amounts demonstrated both: first, although CD28_4-1BB equipped CCRs 
seemed to induce the weakest boost, all combinations increased the release of 
proinflammatory cytokines of the anti-CSPG4 CAR for donor A and B with a factor of at 
least 3.8 and 2.4, respectively (Fig. 40). Second, the results confirmed the findings of the 
trans-experiment. Due to the fact that no benefits for a specific CCR construct became 
apparent in this experiment, in vivo experiments are indispensable to assess the suitability 
and advantageous of a defined CCR structure. 
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Fig. 40 Comparison of CCRs endowed with 4-1BB and/or CD28 endodomains in cis using 
transgenic CD20-positive Mel526 cells. Co-culture assays using CD20-positve Mel526 cells and effector 
cells revealed that CAR T cells that additionally express a CCR sequence induced a boosted release of 
IFN-, IL-2, IL-6 and TNF- without any noticeable difference between the different CCRs. #A and #B 
represent different donors. The indication CSPG4 means that the T cells in this group were CAR transduced. 
The indication after the `&´ (e.g. 4-1BB_4-1BB) stands for the endodomains of the CCR directed against 
CD20. (10000 pg/ml was the detection limit) 
2E4 Mel526CD20_FFluc_eGFP cells were co-cultured with controls or CAR/CCR-positive T cells 
in different E:T ratios for 18 h to measure target cell killing via a bioluminescence-based 
killing assay (Cap.2.5.2). While transgenic CAR and CCR expressing T cells killed in 
average 43.0 ± 17.1% at a 10:1 E:T ratio, T cells that only expressed the CSPG4 CAR 
killed in a range of 18.1 ± 12.1% (Fig. 41A). In combination with a CAR CD28_CD28 CCRs 
showed the highest killing efficiency of 50.0 ± 20.1%, while 4-1BB_4-1BB induced the 
weakest boost of 35.0 ± 25.8% in this experiment. CCR sequence expressing control T 
cells did not show any killing at a E:T ratio of 5:1 or lower (Fig. 41B). Only a moderate 
killing at the highest ratio was observed for 4-1BB equipped CCRs with 12.0 ± 19.1%. T 
cells modified with LV-CD20_5 (4-1BB_CD3), however, killed even at the lowest E:T ratio 
1.25:1 > 40% of the CD20-positive Mel526 cells confirming the susceptibility of this 
transgenic Mel526 cells to a CD20-directed killing (Fig. 41C). In summary, it could be 
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shown that the potential of anti-CSPG4 CARs can be significantly enhanced by using a 
CCR with either 4-1BB_4-1BB or CD28_4-1BB endodomains (Fig. 41D). It was also 
apparent that 4-1BB_4-1BB endowed CCRs have a significantly higher capacity to 
increase the TNF- release than the one equipped with CD28_4-1BB. 
 
Fig. 41 Bioluminescence-based killing assays confirmed the potential of CCRs to enhance the anti-
CSPG4 CAR T cell response. Mel526 cells were co-cultured with either Mock, controls or co-transduced 
T cells in different E:T ratios. Bioluminescence was measured after 18h. (A) CCR supported CAR T cells 
killed 43.0 ± 17.1% CD20-positive Mel526 cells at a 10:1 E:T ratio while anti-CSPG4 CAR T cells without 
CCR killed 18.1 ± 12.1%. (B) CCR endowed T cells did not show a comparable killing of Mel526 cells. (Each 
sample tested in duplicates; n=2). (C) T cells expressing a conventional anti-CD20 sequence efficiently 
lysed transgenic CD20-positive Mel526 cells. (Tested in duplicates; n=1). (D) Overall, the potential of CCRs 
with either 4-1BB_4-1BB (n=7) or CD28_4-1BB (n=6) endodomains to boost the anti-CSPG4 CAR T cell 
response could be confirmed. Thus, CCRs significantly increase the TNF- release only when both CAR 
and CCR were activated (Parametric unpaired t-test with 95% and 99% confidence level). The indication 
CSPG4 means that the T cells in this group were CAR transduced. The indication after the `&´ (e.g. 4-
1BB_4-1BB) stands for the endodomains of the CCR directed against CD20. 
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3.4.4  Improving the experimental boosting set-up 
Although the functionality of anti-CD20 CCRs could be confirmed in vitro, further construct 
modifications were indispensable due to two reasons. First, the generated lentiviral 
constructs encoded the modified IgG1-derived spacer [40] which was eventually 
responsible for the loss of functionality in vivo (Fig. 25). Second, manufacturing of CAR 
T cells that are transgenic for both CAR and CCR is very complex and labor-intensive. 
Hence, a lentiviral construct, namely DC_1, was generated that encodes a PGK promoter 
driven anti-CD20 4-1BB_4-1BB CCR, a P2A element-linked CSPG4-directed CAR 
followed by a T2A element-linked LNGFR (Fig. 42).  
Initially, a human CD8 spacer derived from MB_004 was cloned into the CCR encoding 
construct. Subsequently, a synthesized element which encodes a human CD116 leader, 
a 225.28s-derived scFv with two C-terminally linked cMyc tags, an IgG4 spacer 
(hinge_CH2_CH3) with 4/2 NQ mutation in the CH2 domain [39] as well as a S→P 
substitution in the hinge region [42], 4-1BB, CD3 and a T2A-element linked LNGFR was 
subcloned using Nhe I and Sal I (Cap. 2.2.2).  
 
Fig. 42 Simplified representations of DC_1, an anti-CD20 CCR_anti-CSPG4 CAR encoding lentiviral 
construct. The 4-1BB_4-1BB equipped CCR was modified as following: (A) initially the IgG1 spacer was 
exchanged against a human CD8 spacer and subsequently the EGFR element was replaced with an anti-
CSPG4 CAR_T2A_LNGFR encoding DNA element. (B) The surface expression of the polycistronic vector 
genes can be measured separately by using a PE-linked CD20 peptide for the CCR or specific conjugated 
antibodies for either cMyc (C-terminally linked to the CSPG4-directed scFv) or LNGFR.  
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Lentiviral particles were produced using the standard protocol (Cap. 2.3.6) before T cells 
derived from two donors were transduced with LV-DC_1 (Cap. 2.4.1), magnetically 
selected using LNGFR-directed microbeads (Cap. 2.4.3) and subsequently expanded 
(Cap. 2.3.2) in TexMACS supplemented with 12.5 ng/ml IL-7, IL-15 and TransAct with a 
titer of 1:500 for T cell re-activation. On day 19, the transgenic surface co-expression of 
CCR, CAR and LNGFR was measured and compared using flow cytometry (Cap. 2.3.7) 
as shown for one representative donor (Fig. 43). This analysis, however, revealed a 
discrepancy regarding CCR (PE-linked CD20 peptide), CAR (cMyc-directed conjugated 
antibody) and LNGFR (LNGFR-directed conjugated antibody) staining. Thus, > 60% of 
the T cells were positive for surface protein LNGFR while only 42% were stainable with 
the CD20 peptide or rather 23% with the cMyc-directed antibody. Even though the staining 
protocol has to be optimized, the functionality of the construct was verified enabling to 
perform in vitro experiments to prove whether the change from an IgG1 spacer to CD8 in 
the CCR as well as the implementation of cMyc tags influenced the boosting potential or 
functionality of the chimeric receptors. 
 
Fig. 43 T cells co-expressing the transgenes CCR, CAR and LNGFR confirmed the functionality 
of the polycistronic lentiviral vector DC_1. Activated T cells were transduced with LV-DC_1, magnetically 
enriched and expanded. The transgenic expression of either CCR, CAR and LNGFR was analyzed on day 
19 using appropriate conjugates and flow cytometry. (A) While Mock T cells were negative for all transgenes 
(B) transduced T cells expressed all of them simultaneously.  
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To assess the functionality of both chimeric receptors encoded in one construct, 1E5 CAR 
and CCR co-expressing T cells were co-cultured with 2E4 Mel526 cells and either 1E5 
CD20-positive JeKo-1, CD20-negative JeKo-1 (Cap. 3.1.2) or without any potential CCR 
activator. Mock as well as conventionally generated CCR- and CAR-positive T cells (Cap. 
3.4.3) using the lentiviral constructs CD20_6 with an IgG1 spacer and 4-1BB_4-1BB 
endodomains as well as CSPG4_2 served as control. After 24 h the TNF- release was 
measured in the supernatant (Cap. 2.5.3) showing that the implementation of cMyc tags 
N-terminally to anti-CSPG4 CAR scFv as well as spacer exchange in the CCR had no 
effect on functionality or on boosting potential (Fig. 44A). While CSPG4-directed CAR 
T cells released 1120.8 ± 90.7 pg/ml TNF- in the presence of JeKo-1 only 384.1 ± 
88.6 pg/ml were released in the absence of JeKo-1. Interestingly, the release also 
increased to 1207.6 ± 165.1 pg/ml when co-culturing anti-CSPG4 CAR T cells with CD20-
negative JeKo-1 cells. T cells modified with LV-DC_1, however, showed a > 5 fold 
increase in the TNF- release compared to the anti-CSPG4 CAR control which only 
occurred when JeKo-1 cells were present. Co-culturing this effector cells with CD20-
negative JeKo-1 cells led to the release of 474.1 ± 212.1 pg/ml TNF-, a factor of at least 
14 lower. Similar results were observed for T cells modified with the two independent 
constructs CD20_6 and CSPG4_2. Mock and cell line controls including JeKo-1, JeKo-1 
CD20 ko and Mel526 did not release TNF-. Analyzing the release of IFN- and IL-2 
further confirmed those findings (Fig. 44B). Thus, the CSPG4-directed CAR was 
functional, however, its immune response was boosted only when the CD20 specific CCR 
was activated. 
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Fig. 44 T cells engineered with a polycistronic lentiviral construct encoding an anti-CD20 CCR and 
a CSPG4-directed CAR induce a boosted immune response only when both targets were present. 
Mel526 cells were co-cultured with Mock, anti-CSPG4 CAR controls or CCR/CAR-positive T cells in the 
presence of either CD20-positive or CD20-negative JeKo-1 cells or without any JeKo-1 cells. After 24 h (A) 
TNF- (B) IFN- and IL-2 were measured confirming the functionality of both chimeric receptors; the CCR 
with a shorter CD8 spacer instead of the long IgG1 spacer and the CAR with implemented cMyc tags. Hence, 
an increased release of proinflammatory cytokines was only detectable when both CCR as wells as CAR 
were activated. #A and #B represent different donors. 
  
Results 
 
88 
 
Finally, the killing effiency of DC_1 modified T cells (Cap. 2.4.1) was assessed. For this 
purpose, 2E4 CD20-positve Mel526FFluc_eGFP were co-cultured with 2.5E4 CAR/CCR co-
expressing T cells for 72h using an IncuCyte device (Cap. 2.5.4) (Fig. 45). Mock as well 
as anti-CSPG4 CAR T cells served as control. During the first 24 h the GFP-positive target 
cells showed comparable growth kinetics, independent of the co-cultured effector cells. 
Afterwards, however, only T cells expressing both CAR and CCR were able to efficiently 
eradicate Mel526 cells and thus outperformed anti-CSPG4 CAR T cells. Nevertheless, 
tumor cell growth kinetic decelerated in the presence of CSPG4-directed CAR T cells 
compared to Mock and thus further confirmed the previously determined moderate 
potency of this CAR. 
 
 
Fig. 45 T cells expressing both chimeric receptors CAR and CCR outperformed T cells without any 
additional co-stimulatory ligands in killing assays. CD20-positive Mel526 cells were co-cultured with 
either Mock, anti-CSPG4 expressing CAR T cells or CAR/CCR-positive T cells at an E:T ratio of 1.25 : 1 for 
72h. Killing efficiency was measured using an IncuCyte device revealing a superior lysis of target cells by 
T cells equipped with an anti-CSPG4 CAR and a CD20-directed CCR compared to T cells bearing only the 
CAR. Mock cells did not show any anti-tumorigenic potential. (Tested in duplicates; n=1) 
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4  Discussion 
Genetically engineered T cells not only represent a promising tool for the treatment of 
patients with cancer or infectious diseases but also a great challenge for scientists and 
physicians. Thus, especially the CD19-directed CAR manifested a “paradigm” for the 
treatment of B cell malignancies [106]. Its clinical success, however, cannot be 
generalized. Accordingly, there is still a high demand on technologies with the potential to 
improve the safety of CAR-based therapies to prevent potential severe side effects. 
Furthermore, the effectiveness of CARs, for instance, in a solid cancer setting has yet to 
be validated [107] and it is likely that novel strategies and therapies are required to 
ameliorate T cell function in such settings. In addition, a cost-effective and efficient 
manufacturing process as well as technologies are of utmost importance to further 
promote the emerging field of ACT [108]. 
4.1 Establishment of preclinical protocols, tools and 
technologies 
More and more pharmaceutical and biotechnology companies are growing in the field of 
ACT and the “race to the finish line” as Carl June recently published [109] is in full swing. 
Although all must fulfil the same preclinical requirements for their living drugs, cost-
effectiveness and pace are of utmost importance for the entire product development and 
production process. Accordingly, a continuous development of tools, protocols and cell 
lines is not only advantageous to evaluate the potential of different CAR formats but also 
required to assess novel CAR technologies. 
In this study, a highly efficient, cheap and universally usable molecular biological platform 
was established allowing to generate lentiviral constructs with reduced workload 
compared to conventional technologies. The used Type IIS enzyme enabled cloning 
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without implementation of cloning sites that might encode matrix metalloproteinase 
recognition sites leading to a post-translational protein degradation [110, 111].  
Since nearly 50 years, the Chromium release assay has been widely used, especially to 
determine the cytotoxicity of T cells in vitro and can still be designated as “gold standard” 
[112, 113]. However, due to nuclear radiation of 51Cr, the laborious radioactivity 
measurement, the time-consuming target cell labeling time and the low signal-to-noise 
ratio the flow-based as well as bioluminescence-based cytotoxicity assay established in 
this work offer several advantages [114]. Thus, labeled target cells cannot only be 
distinguished from effector cells but also PI, 7-AAD or Annexin V could be used to further 
differentiate between living and dying cells applying flow cytometric analysis [113]. Due to 
the intracellular ATP-dependent luciferase reaction [115] the bioluminescence assay was 
highly specific and robust compared to the Chromium release assay where membrane-
associated Chromium [116] might underrate the actual cytotoxic potential of CAR T cells. 
By transducing different target cell lines with a lentiviral construct encoding FFluc in 
combination with GFP, different killing assays including flow-based, bioluminescence-
based as well as IncuCyte-based were established enabling to perform highly sensitive 
and high-throughput analysis of cytotoxicity without any additional labeling steps. In 
addition, the generated JeKo-1 knockout clones (Fig. 12) also represent an additional 
valuable tool enabling a comprehensive evaluation of CAR engineered T cells not only 
regarding functionality but also specificity. Especially in the context of the development 
and testing of novel CAR technologies including AND or NOT logic gates those JeKo-1 
clones were the basis of several in vitro and in vivo experiments. The established knockout 
system for both CD19 and CD20 could be further used for the modification of additional 
cell lines expanding the available tool box for additional CAR T cell evaluations.  
Concerns regarding the validity by using genetically modified target cells in preclinical 
studies to assess the cytolytic potential of effector cells are legitimate, however, pose no 
problem particularly for the pursued short-term in vitro assays. The suitability to use this 
transgenic cell lines in vivo was furthermore proved in this study. Thus, a JeKo-1- as well 
as a Raji-derived lymphoma xenograft model was successfully established which was 
verified by IVIS, weight loss and an autopsy revealing a massive expansion of tumorigenic 
cells in combination with an observed splenomegaly [117] (Fig. 15 and Fig. 16). 
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To reduce the discrepancy between preclinical data and clinical outcome [118-120], 
extended systemic approaches are required, however, was beyond the scope of this 
thesis. Overall, this work laid the foundations for a profound preclinical evaluation of CAR 
T cells in vitro as well as in vivo. 
4.2   Anti-CD20 CAR development and testing 
Anti-CD19 CAR expressing T cells have demonstrated a remarkable clinical success in 
several clinical trials including ALL [26, 27, 29], CLL [30, 31] and non-Hodgkin lymphoma 
[28]. Maude et al. [54] recently reported complete remissions in 27 out of 30 (90%) patients 
with relapsed and refractory ALL for up to two years after treating them with CD19-directed 
autologous T cells. Nevertheless, some patients relapsed during the CAR T cell therapy 
due to the deficient CD19 expression which was observed in 60% of this patients [55]. 
Such a loss is generally associated with disease relapse for the patients [57]. An 
explanation for losing this surface protein was provided by Sotillo et al. [56]. They 
confirmed that combinatorial molecular biological mechanisms including frameshifts and 
missense mutations as well as alternative splicing of CD19 led at best to the expression 
of N-terminally truncated CD19 isoforms which the CAR does not recognize anymore.  
CD20 as therapeutic target, however, gains more and more attention. First, CD20 is not 
only expressed on a majority of malignant B cells [44, 121, 122] but also on a minor subset 
of cancer-initiating melanoma cells [60, 61]. Secondly, in contrast to CD19, CD20 is not 
reported to become generally internalized upon antibody binding [44, 58, 59]. The 
expression level of CD20 in B cell malignancies is strongly dependent on type and 
differentiation status of the lymphocytic B cells with relatively low expression in patients 
suffering from CLL or ALL but comparatively high expression in patients with DLBCL as 
well as HCL [121-124]. In summary, CD20 represents an important target which defines 
the basis for the CAR development described in this thesis. 
Based on a gamma-retroviral construct which was kindly provided by H. Abken (ZMMK 
Cologne), in this work, a lentiviral anti-CD20 CAR encoding vector was generated 
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enabling genetic modifications of T cells under state-of-the-art conditions. For safety 
reasons, the lentiviral pRRL used contained a chimeric RSV-HIV 5´ LTR as well as 3´ LTR 
with SIN modification which allowed to produce replication-deficient SIN vectors at high 
titers [102, 103, 125]. In addition to a higher cargo-capacity and the ability to also 
transduce non-dividing cells, lentiviral vectors have not been associated with an increased 
risk of target cell malignant transformation. In contrast retroviruses have been reported to 
show biased genome integration towards proto-oncogenic or tumor suppressive genetic 
loci [126-129]. While retroviral transductions require higher technical efforts including spin 
transduction protocols and cationic polymer-pretreated culture plates [130, 131], lentiviral 
modification of T cells does not necessitate these steps which represent also a 
considerable advantage towards automating the manufacturing process.  
In this thesis, all viral particles were pseudotyped with vesicular stomatitis virus 
glycoprotein (VSV-G) due to the following advantages: I) extensive tropism with the low 
density lipoprotein receptor (LDLR) as entry port, II) high transduction efficiencies and III) 
the possibility to concentrate viral particles due to an outstanding stability [132-134]. A 
very promising alternative to VSV-G pseudotyping, however, would be the use of measles 
virus (MV)-derived glycoproteins H and F changing the tropism specific for CD46 and 
signaling lymphocyte-activation molecule (SLAM). Thus, a cell cycle independent 
transduction would be possible as demonstrated by Frecha et al. [135] allowing to 
transduce even resting T cells which is not possible with the VSG-G pseudotyped lentiviral 
vector due to missing expression of LDLR on unstimulated lymphocytes [136]. Linking an 
scFv to the H protein might modify MV tropism, potentially enabling specific lymphocyte 
subset transduction. Such an approach can contribute to systemic in vivo gene therapy 
strategies with the potential to change the perspective of cellular therapies [137-139]. 
However, hurdles like low titer production need to be overcome. 
The generated anti-CD20 CAR encoding lentiviral construct CD20_1 contained the 
original retroviral CAR nucleotide sequence to initially test the protocols for the generation 
of lentiviral particles, establishing assays and protocols to assess the cytolytic potential of 
CD20-directed CAR T cells and to finally compare the potential of retrovirally and 
lentivirally modified T cells. Accordingly, a three plasmid system (Fig. 18) was used to 
produce lentiviral particles [140]. Viral titer was determined by transducing Jurkat cells 
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revealing a titer of 1.1E9 LV-particles/ml. Although some labs prefer non-functional 
titration methods including real-time qPCR or ELISA protocols [141, 142] to measure their 
titer, in this work, the transgene expression following a limiting dilution was analyzed by 
flow cytometry allowing to quantify functional vectors. Consequently, in contrast to non-
functional methods, more predictable and precise titers could be determined [143] which 
allowed virus-batch independent comparisons of transduced, CAR engineered T cells. 
In a next step, the cell-mediated cytotoxicity of LV-CD20_1 modified T cells was analyzed 
using co-culture assays with autologous B cells as targets to measure both target cell lysis 
as well as effector cell function. The cytokine release assay confirmed that only CD20-
directed CAR T cells, in contrast to untransduced Mock T cells, induced the release of 
proinflammatory cytokines including IFN-, IL-2 and TNF-(Fig. 23). In addition to the 
applied degranulation assay, a flow based killing assay further confirmed anti-target 
reactivity (Fig. 22). Overall, it could not only be shown that high titers of lentiviral particles 
could be produced but also the functionality of the originally transferred anti-CD20 CAR 
was verified. Interestingly, lentivirally modified T cells did not significantly differ from 
retrovirally transduced T cells regarding CD4/CD8 ratio or CAR expression (Fig. 21). 
Nonetheless, the latter induced T cells to release significantly higher amounts of cytokines 
upon encountering their target and in addition killed better at the highest E:T ratio with 
10:1 (Fig. 23B) which was rather unexpected. At E:T ratios lower 5:1, however, the 
observed differences disappear and even changed at the lowest E:T ratio of 1:1 to a higher 
cytotoxicity of lentivirally engineered T cells for two out of three donors tested. As this 
comparison of differently transduced T cells was not only aiming to assess the functionality 
but as well considered the laborious production of retroviral particles, the expensive 
RetroNectin-assisted spin transduction and the high risk of insertional oncogenesis by 
using retroviral particles, especially with regard to an automated manufacturing process 
for engineered T cells and their subsequent use in the clinic, the advantages for lentivirally 
engineered T cells are obvious. Not least, the suitability of the used protocols and 
functionality assays to analyze the potential of gene modified T cells was used for the 
following experiments.  
Discussion 
 
94 
 
4.3  Anti-CD20 CAR construct optimizations 
Essential characteristics of a CAR include intracellular T cell derived activation domains 
as well as a spacer linked antigen binding domain [106]. The latter is predominantly a 
scFv which comprises a heavy and a light chain, connected by a short linker. Ideally, this 
binding moiety is derived from a clinically approved or even tumor specific antibody to 
preferably prevent off-target toxicity as for instance reported by Morgen et al. [41]. 
CD20_1 originally encoded a murine Leu-16 scFv in a vh/vl orientation as published by 
Müller et al. [144] and used by Schmidt et al. [61]. Nevertheless, Till et al. [44] assessed 
both safety and potential of a first generation CAR with a Leu-16 scFv in a vl/vh orientation 
in a proof-of-concept clinical trial (ClinicalTrials.gov Identifier NCT00012207) for the 
treatment of patients with relapsed or refractory NHL or MCL. Even though they observed 
only modest clinical efficacy, Till et al. showed the safety of their anti-CD20 CAR T cells 
and thus defined an important basis for this work. Consequently, the scFv was adapted to 
CD20_2. The construct was further refined by deleting non-assignable sequences 
including a Not I site encoding a potential matrix metalloproteinase recognition site 3´ 
prime of the scFv and several mutations throughout the anti-CD20 CAR encoding 
sequence. Furthermore, the murine kappa chain leader sequence was replaced against 
a human CD8 leader sequence. Accordingly, the Leu-16 scFv was the only non-human 
element and therefore is still potentially immunogenic [145]. To prevent HAMA responses 
limiting T cell persistency as well as anaphylactic reactions after repeated injections in the 
patient the use of an entirely humanized CAR would be advantageous [146, 147] but was 
not available. 
While CD20_2 was still driven by the internal human PGK promoter, in the further modified 
version CD20_3 an EF-1 promoter was used instead. However, both PGK as well as 
EF-1 induced stable transgenic expression in T cells that was slightly higher in the latter 
case as demonstrated by Milone et al. [148, 149]. Given the fact that neither PGK nor EF-
1 was hampering the production of lentiviral particles due to promoter competition as 
described by Schambach et al. [125] and confirmed in this work (data not shown), both 
promoters were suited to drive the CAR sequence transcription. Nevertheless, 
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considering the circumstance that the clinical approved anti-CD19 CAR was also driven 
by the EF-1 promoter [149], this promoter was selected for this study as well. 
Comparing the different constructs in T cells revealed that all of them were functional, 
however, the revised versions with the human CD8 leader sequence, reversed scFv 
orientation and eliminated cloning sites showed a higher cytolytic potential than the initially 
generated construct CD20_1 (Fig. 24). Furthermore, it could be shown that the EF-
1promoter driven construct lysed more JeKo-1 cells (mean 56.7 ± 19.5%) than the 
pendant with the PGK promoter (mean 43.8 ± 11.4%). Consequently, these findings 
confirmed not only the decision for EF-1 but also the need to amend the primary 
construct. In a next step, thus, the extracellular domains including spacer as well as scFv 
were further modified leading to the lentiviral constructs CD20_4 and CD20_5. Both 
encoded a human CD8 spacer instead of the IgG1-derived spacer and in addition the scFv 
orientation in CD20_5 was changed back to vh/vl.  
The important role of the spacer domain in a CAR context has been demonstrated in many 
publications revealing that several aspects are crucial for an optimal CAR T cell 
functionality. Defined spatial biological circumstances between T cell and target cell have 
to be considered and interactions empirically adjusted by varying the extracellular spacer 
length as shown by Hudecek et al. [39]. Nevertheless, in addition, the distance between 
CAR T cell and target cell is decisive as well, enabling the formation of the immunological 
synapse and thus excluding, for instance, CD45 or CD148, phosphatases with large 
ectodomains (> 15 nm) [150]. An ideal point of reference is defined by the fixed distance 
of T cell receptor and major histocompatibility complex (MHC)-peptide complex of 
approximately 13 – 15 nm [150, 151]. In accordance with this hypothesis, CAR T cells 
targeting membrane-proximal antigens are more susceptible to exploit their full cytolytic 
potential compared to those targeting membrane-distal targets [150, 152, 153]. 
Hudecek et al. [39] furthermore proved the discrepancy between in vitro and in vivo testing 
of CAR T cells and thus, in accordance with others, confirmed that FcR binding to the 
spacer is associated with AICD and therefore CAR T cells neither persist nor induce a 
tumor regression in vivo [39, 40, 154, 155]. Consequently, an IgG1 spacer featured with 
a PELLGGPPVAG and ISRIAR mutation was used in this study replacing FcR 
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binding sites against the corresponding sequence derived from IgG2 [40, 156, 157]. While 
all CAR T cells equipped with those spacers showed a high cytolytic potential in vitro, it 
was rather unexpected that the same T cells did not show any anti-tumor reactivity in 
xenograft models (Fig. 25). Indeed, Hombach et al. [40] verified that their IgG1 mutations 
do not interact with FcR expressed on monocytes or NK cells, however, they only focused 
on FcRI (CD64), a high-affinity IgG1 binder in humans (KA approximately 6.5E7 M-1), as 
well as FcRII (CD32), a low affinity IgG1 binding family member (KA approximately 2E5 
M-1) [158], in their in vitro experiments and thus not considering alternative FcRs that 
may bind to the spacer in vivo. A 4/2 NQ modified IgG4 spacer which demonstrated both 
functionality and persistency in xenograft experiments [39] represented a promising 
alternative and was accordingly used for the CAR library, established in this study. 
In summary, not only the spatial distance but also antigen location and FcR binding are 
factors that greatly influence the potential of CAR T cells; accurate clinical predictions, 
though, are not possible at present and thus empirical studies including in vitro and in vivo 
testing are still of utmost importance [39].  
It could also be shown that the CD20-directed CAR constructs CD20_4 (data not shown) 
and CD20_5 efficiently lysed tumorigenic cells and rapidly controlled tumor outgrowth (Fig. 
25). The fact that the scFv orientation vh/vl demonstrated to a slightly better tumor killing 
than vl/vh (data not shown) led to the decision to use the first mentioned for two different 
clinical trials. Nonetheless, due to the clinically unproven scFv orientation, off-target 
toxicity has to be addressed carefully in this trials in order to make a final safety statement 
of this anti-CD20 CAR.  
Overall, an anti-CD20 CAR was developed in the course of this work which demonstrated 
potent anti-tumor reactivity in vitro as well as in vivo. 
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4.4 Facilitating the manufacture of CAR T cells through 
automation 
The dissemination of CAR T cell therapies to a wider number of patients is still hampered 
by the complexity of the manufacturing process requiring both extensively trained 
operators as well as a dedicated infrastructure [66]. Moreover, the multistep procedure 
leaves a wide room for errors that might be associated with fatal consequences during the 
clinical treatment. Hence, the development in this work, of a cGMP-compliant, fully-closed 
and automated TCT Process on the CliniMACS Prodigy platform for the generation of 
engineered T cells was evaluated. The possibility to use this device for the manufacturing 
of CAR T cells at clinical scale was recently demonstrated by collaborators Mock et al. 
and Priesner et al. [70, 71]. Starting from leukapheresis from healthy donors, T cells were 
isolated, activated, transduced, enriched and finally formulated. Not considering minor 
differences regarding selection, cytokine support or lentiviral vector used for the 
transduction, Mock et al. [70] as well as Priesner et al. [71] successfully expanded gene-
modified lymphocytes (5.4 – 28.4 fold; 28 – 42 fold, respectively). Functionality was further 
addressed by Mock et al. [70] verifying the cytolytic potential of CD19-directed CAR T 
cells in vitro as well as in vivo. With this work, several additional aspects were addressed 
to answer the following questions: I) Is it possible to expand engineered T cells starting 
from heavily pre-treated PM? II) Can cryopreserved starting material be used? III) Is it 
possible to develop a robust automated manufacturing process despite the use of different 
devices on different days controlled by varying operators?  
Analyzing expansion, cellular composition, phenotypical characteristics as well as 
functional response (cytolytic potential and cytokine secretion) of either HD- or PM-
derived starting material not only confirmed robustness and reproducibility of the TCT 
Process but also showed that differences regarding the cellular composition of the 
incoming product did not negatively influence quality of the manufactured clinical product 
and that therapeutic doses could be obtained in all cases. Expansion rates were 
comparable and varied from 43 ± 14 fold for HD and from 65 ± 36 fold for PM (Fig. 27G). 
In addition, despite high variances regarding the cellular composition of the incoming 
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product, after twelve days under the established culture conditions favoring a T cell 
outgrowth, the frequency of T cells was nearly identical with 91.3 ± 5.0% for HD and 88.3 
± 7.1% for PM (Fig. 28B). The remaining autologous NKT cells (5.1 ± 2.2% for HD and 
8.0 ± 4.3% for PM), initially designated as `contaminating´ cells (Cap. 3.3.2), might 
represent an additional clinical relevant source of cells for ACT [159]. For instance, they 
have an inherent potential to kill tumors expressing CD1d [160-163]. Consequently, 
autologous NKT cells, even though engineered to express a CAR, most likely do not pose 
a health risk by injecting them back into the patient and could potentially be advantageous. 
However, conclusive evidence is still missing and has to be delivered on the role of gene-
modified NKT cells. 
Albeit the viability of cryopreserved and fresh cells slightly differed during the cultivation 
process, in total no significant differences were observed among HD- and PM-derived 
samples in the final product (90.4 ± 4.3% for HD; 88.4 ± 7.4% for PM; Fig. 27F). As a 
result, either LP, BC or WB, cryopreserved as well as fresh, were qualified as starting 
material for the TCT Process. Interestingly, the procedure allowed to get therapeutic 
doses from limited starting patient material (starting with a fifth of the 1E8 enriched cells 
generally used) (Tab. 9). However, limits of the system using lowest and highest starting 
cell numbers and cells from different stages of patient treatments for various indications 
must be further tested to enable optimal recommendations and meet the reality of clinical 
diversity. 
While Mock et al. [70] cultured their T cells in TexMACS supplemented with human 
recombinant IL-2, Priesner et al. [71] as well as this study used human recombinant IL-7 
and IL-15 supplemented medium. Cieri et al. [75] recently reported about the correlation 
of cytokines used for the T cell culture with specific functional features of the generated 
T cell subset. Indeed, they report that the combination of IL-7 and IL-15 led to the 
generation of TSCM that, due to their inherent stemness-associated potential to self-
renewal and ability to differentiate into potent effector T cells, represent a clinically relevant 
“weapon in adoptive T cell therapy against cancer”. Moreover, they demonstrated that in 
addition to CD3/CD28 stimulation IL-7 is required for the differentiation and maintenance 
of TSCM while IL-15 or, with a reduced extend, IL-2 are suitable and required to induce 
expansion of particularly TSCM. Interestingly, comparing the phenotypical characteristics 
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of HD- and PM-derived final products revealed significant differences in this work. Despite 
using identical culture conditions, TSCM were underrepresented in the PM runs with 8.9% 
compared to 45.0% for HD runs (Fig. 28D). A marked difference between HD and PM was 
the strongly reduced presence of TN in the starting material of PM. Although not proven 
by this work, presence of TN in the starting material seems to be essential in order to 
obtain TSCM in the final product on day twelve. PM came from heavily pre-treated patients 
having undergone several rounds of chemotherapy that can explain a different cellular 
composition and reduced TN compared to HD. If TSCM turn out to be the most effective T 
cell carrier for clinical effectiveness, it may become essential to use starting material from 
PM prior to heavy pre-treatments and possibly move T cell therapy up in the line of 
treatment (before chemotherapy). On the other hand, Robbins et al. [164] proved in their 
studies for the treatment of metastatic melanoma that the persistence of transferred cells 
correlates with the therapeutic efficacy. In line with these findings, Wang et al. [77] 
investigated the engraftment potential of defined T cell subsets and their long-term anti-
tumor activity in a mouse model and figured out that TCM-derived effector cells outperform 
TEM-derived effector cells. Those results were in accordance with Berger et al. [76] who 
showed in macaques that only TCM persisted long-term, preserved a memory T cell pool 
and therefore maintained T cell immunity. Since the cumulative frequency of memory 
T cells in expanded products of HD and PM were comparable in this study (45.0% TSCM 
and 34.0% TCM for HD; 8.9% TSCM and 64.7% TCM for PM) (Fig. 28D) it is possible to 
assume that CAR T cells generated from patient material will be clinically effective. The 
proof will be obtained during clinical applications of the results of this work in the coming 
years. 
A further difference in the manufacturing protocol between Priesner et al. [71] and this 
work was the isolation of CD62L-positive cells in contrast to CD4/CD8 selection. Thus, 
Priesner and his colleagues achieved frequencies > 95% CD62L-positive cells comprising 
mainly TN (>75%) and smaller populations of TCM. However, due to the following three 
reasons CD62L enrichment was not considered in the present study: I) this marker gets 
downregulated upon cryopreservation [71] and thus would hamper the initial selection 
step. II) CD62L is widely expressed on hematopoetic cells including monocytes, NK cells, 
granulocytes and B cells [165-168] and especially the co-enrichment of monocytes is 
Discussion 
 
100 
 
associated with a reduced transduction efficiency and an impaired expansion of T cells as 
reported by Stroncek et al. [169] in accordance with own findings (data not shown). III) 
The selection of CD62L-positive malignant B cells, their subsequent genetic modification 
during the transduction and the even low possibility to reinfuse those cells back into the 
patient would be an undeniable safety risk for ACT. 
Finally, the cytolytic potential of automatically manufactured CAR T cells was assessed 
and compared in vitro revealing that both HD- and PM-derived effector cells efficiently 
lysed CD20-positive target cells (Fig. 29C & D). Thus, at an E:T ratio of 1:1 the mean 
killing frequency for HD was 44.2 ± 19.3% and only slightly higher than the frequency of 
PM with 39.3 ± 21.3% but not significantly different. Although the generated CAR T cells 
showed cytotoxic function in vitro, their full function was better demonstrated in vivo using 
a challenging model of a seven day established lymphoma xenograft model, 
demonstrating that only CD20-directed CAR T cells, not Mock T cells, were able to control 
tumor outgrowth (Fig. 30). Even though similar results are expected for PM-derived 
engineered T cells, the experimental proof is still missing and has to be assessed. 
Alternatives for the production of engineered T cells were, inter alia, published by 
Ramanayake et al., Tumaini et al. or Lu et al. [67-69]. In contrast to the last two 
publications, Ramanayake et al. used gas-permeable G-Rex10 flasks (Wilson Wolf 
Manufacturing) to expand piggyBac pre-transfected T cells that were either stimulated 
with irradiated PBMC or NALM-6 cells. After 23 days, their protocol yielded in up to 765 
fold expansion for HD-derived samples (72% median CAR expression) and 180 fold 
expansion when PM (81% median CAR expression) was used as starting material. 
Tumaini et al. as well as Lu et al. transduced and expanded their T cells in PermaLife 
bags (OriGen Biomedical). Within eleven days, Tumaini and colleagues achieved a 10.6 
fold expansion with a viability of 70.4% and a frequency of 68.4% CAR-positive T cells. 
With the protocol defined by Lu et al. expansion rates ranging from 4.5 – 16 fold were 
attained within six days (viability was not determined; transduction efficiency: 43.6 ± 8.3%). 
Even though all protocols provided a possibility for the manufacturing of engineered T 
cells, there are several disadvantages compared to the CliniMACS Prodigy based TCT 
Process. Especially multiple open handling steps that were required, for instance, for 
sample preparations, transfection or RetroNectin-coating and subsequent washing of their 
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expansion bags greatly increase the risks of contaminations. In addition, not enriching 
T cells in the beginning of the process also increases the probability to genetically modify 
malignant B cells and to subsequently administer those cells back into the patient. Finally, 
the biodegradable MACS GMP T Cell TransAct for the polyclonal T cell activation was 
used instead of anti-CD3/anti-CD28 Dynabeads (Invitrogen). Accordingly, a bead-removal 
step was not required in the TCT Process. 
Last but not least, there are regulatory requirements for the clinical manufacture of ATMPs 
that are requesting class A/B (GMP EU) cleanrooms (2003/94/EC of 8 October 2003) to 
“minimize the risk of error and to permit effective cleaning and maintenance in order to 
avoid contamination, cross contamination and, in general, any adverse effect on the 
quality of the product”. Those cleanrooms are a significant investment on basis of the 
infrastructure required, while one CliniMACS Prodigy device is not only space-saving but 
also represents a closed entity meeting relevant standards [66]. Overall, although 
alternative protocols for the manufacturing of engineered T cells using semi-closed 
systems were successfully applied [67-69], the fully-closed TCT process offers many 
benefits including a lower contamination risk, high robustness and in addition an improved 
cost efficiency especially regarding facility and personal expenses. 
In conclusion, this study proved that the TCT Process yields, independent of operator or 
device, a clinically relevant dose of potent engineered T cells. Furthermore, it was 
demonstrated that a large variety of starting cell products can be used. Consequently, the 
fully-closed, automated cGMP-compliant process is suited to manufacture gene-modified 
T cells under state-of-the-art conditions and thus might promote a further distribution of 
CAR-based and/or other individualized therapies towards patients benefits. Although this 
work on automation defines a huge step in this direction, further work is required to 
develop additional technological advances to allow the manufacturing of patient specific 
cell therapies as simple as an off-the-shelf drug. 
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4.5   Boosting CAR T cell responses 
Recently, Zhao et al. [50] designated CD19-directed CAR T cells as “poster child for CAR 
therapies” as complete remission rates > 88% have been repeatedly reported using this 
artificial receptor [52-54]. However, headlines in the context of solid tumor treatment using 
CAR T cells are less promising. Notwithstanding the toxicity originating from CAR T cells 
especially in those settings, the clinical responses are sobering. The best data reported 
so far was generated in a clinical trial with a GD2-directed CAR for the treatment of 
neuroblastoma (ClinicalTrials.gov Identifier NCT00085930) in which 3 out of 11 patients 
achieved complete remission [170].  
Reasons for the limited success of CAR engineered T cells for the treatment of solid 
tumors are not fully understood yet, but surely associated with tumor-associated 
histopathological features which impedes tumor infiltration and creates a highly 
immunosuppressive tumor-microenvironment including intrinsic factors such as hypoxia, 
low pH or nutritional depletion [78, 81, 171] as well as mechanisms preventing T cell 
activation or maintenance of an activated status. The tumor-induced recruitment of 
immune suppressor cells such as Treg, MDSC or immature dendritic cells and the 
upregulated expression of inhibitory receptors are further aggravating factors [49, 79]. 
Approaches that support a strong activation of T cells by for instance suppressing the 
breaks of the immune response (e.g. anti-PD-1, anti-CTLA-4 blockade) have shown that 
T cells can overcome such hurdles and deliver anti-tumor responses even in settings of 
established solid tumors [16-18]. Melero et al. [88, 89] also demonstrated that an artificial 
co-stimulation led to an increased T cell immunity circumventing the challenges that are 
associated with the inhospitable tumor-microenvironment. Thus, they not only 
demonstrated that 4-1BB-directed monoclonal agonist antibodies can be systemically 
administered which induced a strong T cell-mediated anti-tumor immunity but they also 
showed that engineered P815 tumor cells expressing 4-1BBL (CD137L) strongly 
increased the potential of tumor-reactive T cells. Even though their findings confirmed the 
possibility to boost the T cell immunity, both technologies are associated with risks as well 
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as limitations including, amongst others, a non-specific T cell activation and poor clinical 
success [172-174].  
Nevertheless, inspired by these findings, Stephan et al. [90] proved that genetically 
engineered T cells expressing CD80 and 4-1BBL can provide both auto-co-stimulation as 
well as trans-co-stimulation and thus strengthens T cell immunity in vitro as well as in vivo. 
They compared additional combinations of co-stimulatory ligands including OX40L, CD70 
or CD30L and demonstrated that CD80 and 4-1BBL led to the highest T cell boost. The 
T cell associated cis- as well as trans-stimulation has two decisive advantages compared 
to the technologies mentioned above: I) the T cell boost is locally restricted and thus does 
not compromise safety by a general T cell activation. II) Tumor engineering is not required 
for the approach to be highly effective.  
It was a striking finding that CAR T cells that additionally express a 4-1BBL outperformed 
CAR T cells without any extra stimulation in vivo [50]. This approach demonstrated the 
importance of constitutively expressed co-stimulatory ligands as tools to ameliorate the 
CAR T cell immunity. The present work, however, used CCRs based on a modular design 
instead of naturally occurring ligands to induce a T cell boost and thus additionally 
addressed specificity and adjustability. Based on a melanoma setting with CSPG4-
directed CAR T cells and a CCR specific for CD20 first proof-of-principle experiments 
were conducted. One advantage was that appropriate scFvs used in CAR formats were 
already published, however, potency of those anti-CSPG4 CARs can in the best case only 
be regarded as moderate [61, 84, 175]. Though, such scFvs were preferred in order to 
better assess and compare the potential benefit of different CCRs. A 225.28s-derived 
scFv with a long IgG4 spacer outperformed all other constructs (Fig. 31) in in vitro 
functionality assays (data not shown) and thus was used to evaluate the CCR related 
boosting concept. CCRs had to be designed in a way that they only enhance an already 
existing T cell response and were not allowed to induce lysis or T cell proliferation on their 
own. Initial CCRs comprised different combinations of 4-1BB, CD28 and CD3. While 4-
1BB and CD28 represent the conventional `signal 2´ for T cell activation, the latter was 
experimentally chosen particularly with regard to the single immunoreceptor tyrosine-
based activation motif (ITAM) [176] and a superior functionality in an alternative setting 
with genetically engineered T cells (A. Kaiser, Miltenyi Biotec, unpublished data).  
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Initial in vitro experiments revealed the potential of defined CCRs to enhance the CAR T 
cell immunity in trans. Here we demonstrate, to our knowledge for the first time, that CCRs 
equipped with either 4-1BB_4-1BB or CD28_4-1BB strongly increase the release of 
proinflammatory cytokines only upon a simultaneous activation of both CAR and CCR (Fig. 
34 and Fig. 35). While for this first experiments autologous B cells were used to activate 
the CCR in trans, in following experiments CD20-positive JeKo-1 cells were used. This 
was mainly due to the experimental range requiring high quantities of CD20-positive cells 
which could not be provided for all donors. Initial concerns with regard to a different co-
stimulation potential of cell lines and autologous primary cells were dismissed after 
demonstrating comparable results in terms of T cell boost function in the cis experiments 
(Fig. 35). In a next step, the relevance of 4-1BB and CD28 co-stimulation was further 
investigated especially with regard to signaling domains and resulting boost. For this 
purpose, additional constructs with other combinations of 4-1BB and CD28 were 
generated (Fig. 36) and tested in trans as well as in cis. Surprisingly, all novel CCRs 
enhanced the release of TNF- with a factor > 50 (Fig. 38). A direct comparison was 
difficult and due to the varying frequency of CAR and CCR co-expressing T cells (31 – 
69%) not possible (Fig. 37B), but also not compulsory since this experiment aimed to 
exclude candidates for following in vivo experiments in which the different formats will be 
finally assessed. This study not only showed that the implementation of CCRs led to an 
increased release of cytokines (Fig. 39 & Fig. 40) but also that more tumor cells were 
eradicated by T cells expressing CAR and CCR compared to CAR T cells without any 
additional co-stimulation (Fig. 41). 
Even though this study proved protocols for the generation of CAR and CCR expressing 
T cells and furthermore confirmed the functionality of different CCRs in vitro, upcoming in 
vivo experiments necessitated further improvements. The IgG1-derived CCR spacer, 
which was most likely responsible for the loss of functionality of the CD20 CAR in vivo 
(Fig. 25) was deemed suboptimal and had to be exchanged against the CD8 spacer which 
was already shown to be effective in xenograft models. Furthermore, a polycistronic 
lentiviral vector encoding for CAR as well as CCR was cloned into a single vector (Fig. 
42) which facilitated the complex and labor-intensive generation of this genetically 
engineered T cells. To confirm the expression of every single element after a transduction 
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with LV-DC_1, the anti-CSPG4 CAR was further modified with two cMyc tags, 
implemented 3´ of the scFv sequence. Thus, the CCR was stainable with the PE-labeled 
CD20 peptide, CAR and LNGFR could be measured using anti-cMyc and anti-LNGFR 
antibodies, respectively. Discrepancies regarding CAR, CCR and LNGFR measurement 
(Fig. 43) were rather unexpected since the transgenic expression was based on a single 
mRNA from a polycistronic DNA element, driven by a single promoter. The challenge of 
using different labeling reagents with different affinities for their ligand may in part be 
responsible for the differences in frequencies observed. This is, however, unlikely to 
explain the extent of the differences and other factors such as steric hindrances or 
physical CAR/CCR internalization must be considered. Further dedicated studies are 
required to understand why each of the three proteins were not systematically co-
expressed. It will be interesting to study the persistence of T cells infused in vivo and their 
pattern of CAR and CCR expression (for e.g. potential preferential persistence of double 
positive T cells).  
Finally, the functionality of the tri-cistronic LV-DC_1 engineered T cells was shown for 
cytokine release as well as killing experiments (Fig. 44 and Fig. 45). Accordingly, neither 
the CCR spacer exchange nor the implementation of cMyc tags negatively influenced 
functionality of both chimeric receptors. Nevertheless, in vivo experiments have to be 
conducted to evaluate different CCRs and their impact with regard to T cell persistence, 
anti-tumor efficacy and safety. Schneider et al. [177] recently pointed to the narrow ridge 
between functionality and toxicity of CAR T cells in vivo. They demonstrated that T cells 
co-expressing two highly effective CARs which were supposed to kill Raji cells in a 
xenograft model, although being very efficacious, were associated with a massive death 
of mice. The authors thus hypothesized that the large release of proinflammatory 
cytokines, as already detected in vitro, and the subsequent resulting cytokine storm were 
mainly responsible for the acute toxicity observed in the animal model. Considering the 
fact that mice, in contrast to human patients, do not receive any complementary therapy 
including corticosteroids or specific cytokine antagonists as an acute toxicity treatment 
[178-180] no conclusions regarding the CCRs established during this work should be 
neglectfully drawn especially with regard to the fact that the combination of CAR and CCR 
may be safer than the use of two CARs. In addition, it should be noted that Schneider et 
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al. [177] used a leukemia xenograft model with a high tumor burden and consequently 
induced a systemic toxicity. Locally triggered effects, for instance, by treating solid tumors, 
though, would most likely be associated with a more moderate cytokine release syndrome 
in the same animal model. Should it become apparent that CD20-directed CCRs, in 
combination with a CAR, induce the release of high amounts of proinflammatory cytokines 
upon a simultaneous activation and thus are toxic, alternative approaches including 
artificial CCR targets could be an ideal solution. Accordingly, CCR activation could not 
only be precisely induced but also controlled in terms of intensity. Furthermore, it is 
expected that an exclusive CCR activation will, due to a strong co-stimulation, ensure 
survival and persistency of CAR T cells. In this context, findings from Long et al. [38] 
suggest that especially 4-1BB, but not CD28, prevents an early T cell exhaustion and 
consequently improve persistence. They supported these claims with gene expression 
profiles of CAR T cells equipped either with 4-1BB or CD28 co-stimulation domains. Thus, 
the analysis of 4-1BB equipped CARs revealed an upregulation of transcription factors 
that were, amongst others, associated with memory differentiation (KLF6, JUN and 
JUNB4) [181] and anti-apoptotic pathways, instead of a stronger expression of inhibitory 
or exhaustion-regulating factors (TBX21, EOMES, Blimp-1 and IKZF2, LAG3, TIM-3, 
CTLA4, BTLA and CD244) [72, 182-185] as detected for the CD28 counterpart [38]. Even 
though those CAR findings cannot be directly transposed to CCRs without a CD3 
stimulation motif that also influences the fate of T cells, other publications are also 
underlining the importance of 4-1BB signaling in CAR-independent settings [186, 187]. 
Chmielewski et al. [188] refer to the beneficial effects of a locally induced release of 
proinflammatory cytokines that alter the tumor microenvironment and trigger immune 
effector cells. For this purpose, Chmielewski and co-workers generated `T cells redirected 
for universal cytokine killing´ (TRUCKs) and proved that a CAR activation that additionally 
resulted in a specific release of IL-12 led to an improved tumor eradication. The 
combination of TRUCKs, the so-called fourth generation of CAR T cells [189] with CCRs 
may open up increased therapeutic windows [190-192]. The possibility, however, to 
harness the immune system is what makes CAR T cell therapies so attractive but 
potentially increasing T cell function will inevitably lead to increased risks of inducing 
toxicities. A challenge that the field is likely to address in the next years. 
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Particularly combinations of CARs with low affinity scFvs that spare low level target 
antigen expression in basal tissues and CCRs as tools to boost their limited anti-
tumorigenic potential opens up a wide range of clinical therapies as shown in this work. 
However, further work is required to assess the potential of CCRs also in combinations 
with high affinity scFvs which might further increase the scope of this tool.  
Overall, next experimental steps will include in vivo studies to basically analyze CCR 
activation kinetics, compare CCRs equipped with different co-stimulatory domains with 
regard to persistency and potential to boost various CARs and finally widen the potential 
clinical applications from melanoma to additional tumors including triple negative breast 
cancer and acute myeloid leukemia. 
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4.6   Conclusions and outlook 
Primary objectives of the work presented here were to design CAR T cells for clinical 
applications, improve their manufacturing and further development of CAR technologies 
to potentially improve the treatment outcome. In this respect, the development and 
manufacturing of CD20-directed CAR T cells was investigated towards the use in two 
independent clinical trials. Starting from a retroviral vector, a lentiviral anti-CD20 CAR 
encoding construct was generated, further optimized and thoroughly analyzed in hereby 
established in vitro as well as in vivo experiments. In addition, this work proved the 
robustness of the cGMP-compliant TCT Process and thus demonstrated that potent 
engineered T cells, independently of starting material, can be automatically manufactured 
which might facilitate the dissemination of ACT.  
In future, the use of fully humanized CARs must be preferred to prevent HAMA responses 
and anaphylactic reactions (Cap. 4.3). Accordingly, a screening for human scFvs targeting 
CD20 is currently in the focus of our efforts. The same applies to possibilities to prevent 
long-term side-effects like B cell aplasia caused by CARs for the treatment of B cell 
malignancies [193]. In this context, the implementation of clinically approved suicide 
genes like Herpes simplex-derived thymidine kinase (TK) [194] or an artificial inducible 
caspase 9 [195] would be a first step, however, potential improvements for both systems 
are required [196, 197]. Thus, particularly combinations of molecular biological 
approaches and epitope based CAR T cell elimination mechanisms such as RQR8 [198] 
offer promising opportunities for ACT. Switchable-CAR [199, 200] or Split-CAR [85, 201] 
approaches represent alternative technologies that address both safety as well as 
preventing tumor escape. Treatment can be controlled by administration defined 
concentrations of one or several antibodies. 
T cell engineering will additionally be a key aspect of following investigations. In this 
respect, we want to address both alternative CAR delivery systems and targeted 
integrations. While most CAR T cells are generated using retroviral and lentiviral vectors, 
Monjezi et al. [202] recently demonstrated the advantages of non-virally modified T cells 
using a Sleeping Beauty system in combination with minicircle encoded CARs. Using 
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Transposases to modify T cells instead of viral constructs has several advantages 
including higher cargo-capacity, better safety profile, a superior efficiency as well as an 
improved cost efficiency [202-204]. Additionally, in this context, further amendments could 
be realized by combining the Sleeping Beauty system or other transposon systems with 
the CRISPR/Cas9 technology which would not only allow a knock-out of the endogenous 
T cell receptor which could open the door for allogenic therapies but also enable 
adjustable CAR expression after a targeted integration of a gene-trap construct that has 
been shown to improve CAR T cell functionality [205].  
The treatment of solid tumors still poses a particular challenge. Hence, the identification 
of tumor associated antigens and the highly immunosuppressive tumor microenvironment 
have to be specifically addressed. Even though, this study proved the use of CCRs to 
potentiate CAR T cell function in vitro, subsequent studies have to focus on in vivo 
experiments to, firstly, investigate the functionality of our boosting approach and, secondly, 
assess and compare the different CCRs as well as their activation kinetics. Finally, the 
combination of CCRs is conceivable with alternative approaches including 
transcriptionally controlled CCR expression to specifically induce a boost or enhancing 
naturally occurring immune effector cells like TILs. 
Despite the major clinical achievements and the resulting increased significance of CAR 
T cells for the treatment of cancer and infectious diseases, a retrospective analysis of 
scientific and medical reports highlights the challenges that must be addressed to improve 
CAR designs. Thus, an optimal CAR treatment will avoid tumor escape, will be highly 
efficacious, includes off-switch possibilities for better control, shows no adverse events 
and no off-target toxicity in order to be safe. Even though multidisciplinary collaborations 
are required to meet all demands, translational research has a particular responsibility 
and is already providing some solutions. Consequently, relapses due to the 
downregulation of targeted antigens could be virtually prevented by the use of dual-CAR, 
Tan-CAR or tandem-CAR approaches [55, 177, 206, 207]. Generally, the focus from 
mono-therapies has to shift towards versatile treatments including not only conventional 
clinical approaches such as chemotherapy and monoclonal antibodies but also 
checkpoint-inhibitors, cancer vaccination and other immune effectors like B cells, TILs, 
NK cells, NKT cells or cytokine-induced killer (CIK) cells. 
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